homeopathy "allergic rhinitis" randomized controlled trial

homeopathy effectiveness allergic rhinitis clinical evidence 2024 2025

PMID: 30699444

homeopathy "allergic rhinitis" systematic review meta-analysis

PMID: 28437146

PMID: 16675332

What is your thesis topic? Is it on homeopathy in allergic rhinitis (from our previous discussion), or a different topic? · What do you need help with? · What type of study design are you using or planning?

Which area of homoeopathy interests you most for your thesis? · What kind of study can you realistically do as an intern? · Any specific disease area you want to focus on?

BHMS internship thesis dissertation topics homoeopathy respiratory 2024 2025 India

homeopathy allergic rhinitis asthma clinical study individualized

homeopathy "allergic rhinitis" prospective observational clinical study

BHMS thesis format India homoeopathy dissertation chapter structure university guidelines

ls /home/daytona/workspace/ 2>/dev/null || echo "workspace empty or not found"

mkdir -p /home/daytona/workspace/bhms-thesis && cat > /home/daytona/workspace/bhms-thesis/thesis.js << 'JSEOF' const { Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell, HeadingLevel, AlignmentType, BorderStyle, WidthType, VerticalAlign, PageNumber, Header, Footer, PageBreak, ShadingType } = require('docx'); const fs = require('fs'); const titlePage = [ new Paragraph({ children: [new TextRun({ text: "", break: 1 })], spacing: { after: 400 } }), new Paragraph({ children: [new TextRun({ text: "A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE EFFECTIVENESS OF INDIVIDUALIZED HOMOEOPATHIC TREATMENT IN PATIENTS OF ALLERGIC RHINITIS", bold: true, size: 28, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 600 } }), new Paragraph({ children: [new TextRun({ text: "A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF", size: 22, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 200 } }), new Paragraph({ children: [new TextRun({ text: "BACHELOR OF HOMOEOPATHIC MEDICINE AND SURGERY (BHMS)", bold: true, size: 24, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 600 } }), new Paragraph({ children: [new TextRun({ text: "Submitted by:", size: 22, font: "Times New Roman" })], alignment: AlignmentType.CENTER }), new Paragraph({ children: [new TextRun({ text: "Dr. [Candidate Name]", bold: true, size: 24, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 200 } }), new Paragraph({ children: [new TextRun({ text: "Internship Batch: [Year]", size: 22, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 400 } }), new Paragraph({ children: [new TextRun({ text: "Under the Guidance of:", size: 22, font: "Times New Roman" })], alignment: AlignmentType.CENTER }), new Paragraph({ children: [new TextRun({ text: "Dr. [Guide Name], [Designation]", bold: true, size: 24, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 200 } }), new Paragraph({ children: [new TextRun({ text: "Department of Practice of Medicine", size: 22, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 600 } }), new Paragraph({ children: [new TextRun({ text: "[Name of Homoeopathic Medical College & Hospital]", bold: true, size: 24, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 200 } }), new Paragraph({ children: [new TextRun({ text: "[Affiliated University Name]", size: 22, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 200 } }), new Paragraph({ children: [new TextRun({ text: "[City, State]", size: 22, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 200 } }), new Paragraph({ children: [new TextRun({ text: "[Year]", bold: true, size: 24, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 400 } }), ]; function heading1(text) { return new Paragraph({ text: text, heading: HeadingLevel.HEADING_1, spacing: { before: 400, after: 200 }, pageBreakBefore: true }); } function heading2(text) { return new Paragraph({ text: text, heading: HeadingLevel.HEADING_2, spacing: { before: 300, after: 150 } }); } function heading3(text) { return new Paragraph({ text: text, heading: HeadingLevel.HEADING_3, spacing: { before: 200, after: 100 } }); } function para(text) { return new Paragraph({ children: [new TextRun({ text: text, size: 24, font: "Times New Roman" })], alignment: AlignmentType.JUSTIFIED, spacing: { after: 200, line: 360 } }); } function bullet(text) { return new Paragraph({ children: [new TextRun({ text: text, size: 24, font: "Times New Roman" })], bullet: { level: 0 }, spacing: { after: 120 } }); } function boldPara(label, text) { return new Paragraph({ children: [ new TextRun({ text: label + ": ", bold: true, size: 24, font: "Times New Roman" }), new TextRun({ text: text, size: 24, font: "Times New Roman" }) ], alignment: AlignmentType.JUSTIFIED, spacing: { after: 200, line: 360 } }); } // CERTIFICATE PAGE const certificatePage = [ new Paragraph({ children: [new PageBreak()] }), new Paragraph({ children: [new TextRun({ text: "CERTIFICATE", bold: true, size: 30, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 400 } }), para("This is to certify that the dissertation entitled \"A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE EFFECTIVENESS OF INDIVIDUALIZED HOMOEOPATHIC TREATMENT IN PATIENTS OF ALLERGIC RHINITIS\" is a bonafide work carried out by Dr. [Candidate Name], BHMS Intern, [Name of Institution], under my supervision and guidance."), para("This work has not been submitted previously in part or full for the award of any degree or diploma by this or any other University."), new Paragraph({ children: [new TextRun({ text: "", break: 3 })], spacing: { after: 400 } }), new Paragraph({ children: [new TextRun({ text: "Guide:", bold: true, size: 24, font: "Times New Roman" })], spacing: { after: 100 } }), para("Dr. [Guide Name]"), para("[Designation]"), para("Department of Practice of Medicine"), para("[Institution Name]"), new Paragraph({ children: [new TextRun({ text: "", break: 2 })], spacing: { after: 200 } }), new Paragraph({ children: [new TextRun({ text: "Head of Department:", bold: true, size: 24, font: "Times New Roman" })], spacing: { after: 100 } }), para("Dr. [HOD Name]"), para("Department of Practice of Medicine"), para("[Institution Name]"), new Paragraph({ children: [new TextRun({ text: "", break: 2 })], spacing: { after: 200 } }), new Paragraph({ children: [new TextRun({ text: "Principal:", bold: true, size: 24, font: "Times New Roman" })], spacing: { after: 100 } }), para("Dr. [Principal Name]"), para("[Institution Name]"), para("Date: _____________"), para("Place: _____________") ]; // DECLARATION PAGE const declarationPage = [ new Paragraph({ children: [new PageBreak()] }), new Paragraph({ children: [new TextRun({ text: "DECLARATION BY THE CANDIDATE", bold: true, size: 28, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 400 } }), para("I, Dr. [Candidate Name], hereby declare that the dissertation entitled \"A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE EFFECTIVENESS OF INDIVIDUALIZED HOMOEOPATHIC TREATMENT IN PATIENTS OF ALLERGIC RHINITIS\" is my own work and has been carried out under the guidance of Dr. [Guide Name], Department of Practice of Medicine, [Institution Name]."), para("I further declare that this dissertation has not been submitted for any degree, diploma, or other similar title to any university or institution before."), para("The information derived from other sources has been duly acknowledged in the text and references."), new Paragraph({ children: [new TextRun({ text: "", break: 4 })], spacing: { after: 400 } }), para("Signature of the Candidate"), para("Name: Dr. [Candidate Name]"), para("Date: _____________"), para("Place: _____________") ]; // ACKNOWLEDGEMENT const acknowledgementPage = [ new Paragraph({ children: [new PageBreak()] }), new Paragraph({ children: [new TextRun({ text: "ACKNOWLEDGEMENT", bold: true, size: 28, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 400 } }), para("I express my deep sense of gratitude and heartfelt thanks to my guide, Dr. [Guide Name], for their constant encouragement, invaluable guidance, and unwavering support throughout the course of this work. Their scholarly inputs and critical evaluation at every stage of this dissertation have been instrumental in shaping this work."), para("I am deeply indebted to the Head of the Department of Practice of Medicine, Dr. [HOD Name], for providing all necessary facilities and inspiration to complete this study."), para("I am grateful to the Principal, Dr. [Principal Name], for granting me permission to carry out this research and for providing the institutional infrastructure."), para("I sincerely thank all the patients who voluntarily participated in this study and cooperated with patience and trust. Without their consent and cooperation, this study would not have been possible."), para("I express my gratitude to the staff of the Outpatient Department for their assistance in patient recruitment and follow-up."), para("Last but not least, I thank my family and friends for their continuous moral support and encouragement throughout this endeavour."), new Paragraph({ children: [new TextRun({ text: "", break: 2 })], spacing: { after: 200 } }), para("Dr. [Candidate Name]"), para("[Institution Name]"), para("Date: _____________") ]; // ABBREVIATIONS const abbreviationsPage = [ new Paragraph({ children: [new PageBreak()] }), new Paragraph({ children: [new TextRun({ text: "LIST OF ABBREVIATIONS", bold: true, size: 28, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 400 } }), new Table({ width: { size: 100, type: WidthType.PERCENTAGE }, rows: [ new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Abbreviation", bold: true, size: 22 })] })], width: { size: 30, type: WidthType.PERCENTAGE } }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Full Form", bold: true, size: 22 })] })], width: { size: 70, type: WidthType.PERCENTAGE } }) ]}), ...([ ["AR", "Allergic Rhinitis"], ["ARIA", "Allergic Rhinitis and its Impact on Asthma"], ["BHMS", "Bachelor of Homoeopathic Medicine and Surgery"], ["CCRH", "Central Council for Research in Homoeopathy"], ["IgE", "Immunoglobulin E"], ["IHT", "Individualized Homoeopathic Treatment"], ["NIHT", "Non-Individualized Homoeopathic Treatment"], ["OPD", "Outpatient Department"], ["RCT", "Randomized Controlled Trial"], ["RQLQ", "Rhinoconjunctivitis Quality of Life Questionnaire"], ["SAR", "Seasonal Allergic Rhinitis"], ["PAR", "Perennial Allergic Rhinitis"], ["SPT", "Skin Prick Test"], ["TNSS", "Total Nasal Symptom Score"], ["TOSS", "Total Ocular Symptom Score"], ["VAS", "Visual Analogue Scale"], ["WHO", "World Health Organization"] ].map(([abbr, full]) => new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: abbr, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: full, size: 22 })] })] }) ]}))) ] }) ]; // ABSTRACT const abstractPage = [ new Paragraph({ children: [new PageBreak()] }), new Paragraph({ children: [new TextRun({ text: "ABSTRACT", bold: true, size: 28, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 300 } }), boldPara("Title", "A Prospective Observational Study to Evaluate the Effectiveness of Individualized Homoeopathic Treatment in Patients of Allergic Rhinitis"), boldPara("Background", "Allergic rhinitis (AR) is an IgE-mediated inflammatory condition of the nasal mucosa characterized by sneezing, rhinorrhea, nasal congestion, and nasal itching. It affects an estimated 10-40% of the global population and represents a significant burden in terms of quality of life and healthcare costs. Homoeopathy, as an individualized system of medicine, offers a potentially effective alternative or complementary treatment for AR."), boldPara("Aims and Objectives", "To evaluate the effectiveness of individualized homoeopathic treatment in patients of allergic rhinitis using the Total Nasal Symptom Score (TNSS) and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)."), boldPara("Study Design", "Prospective observational study."), boldPara("Setting", "Outpatient Department (OPD) of [Institution Name]."), boldPara("Duration", "Six months."), boldPara("Sample Size", "40 patients satisfying inclusion criteria."), boldPara("Methods", "Patients diagnosed with allergic rhinitis were enrolled after written informed consent. Detailed homoeopathic case-taking was performed for each patient. Individualized remedy selection was based on totality of symptoms using standard homoeopathic repertory (Kent / Complete Repertory). TNSS and RQLQ scores were recorded at baseline, 1 month, 3 months, and 6 months. Statistical analysis was done using Wilcoxon signed-rank test and paired t-test."), boldPara("Expected Results", "A significant reduction in TNSS and RQLQ scores is anticipated at 3 and 6 months of treatment, indicating improvement in nasal symptoms and quality of life."), boldPara("Conclusion", "Individualized homoeopathic treatment is expected to show a statistically significant improvement in the symptoms and quality of life of patients with allergic rhinitis."), boldPara("Keywords", "Allergic Rhinitis, Homoeopathy, Individualized treatment, TNSS, RQLQ, Simillimum") ]; // CHAPTER 1 - INTRODUCTION const chapter1 = [ heading1("CHAPTER 1: INTRODUCTION"), heading2("1.1 Background"), para("Allergic rhinitis (AR) is one of the most prevalent chronic conditions worldwide, affecting approximately 10-40% of the global population, with an increasing prevalence in developing countries including India. It is defined as a symptomatic disorder of the nose induced by an IgE-mediated inflammation of the nasal membranes after allergen exposure, characterized by one or more of the following symptoms: nasal congestion, rhinorrhea, sneezing, and nasal itching."), para("Despite its seemingly benign nature, AR significantly impairs quality of life, academic performance, work productivity, and sleep. It is closely associated with comorbidities such as bronchial asthma (which co-exists in approximately 80% of patients with allergic asthma), chronic sinusitis, otitis media, and atopic dermatitis. The socioeconomic burden is considerable, with significant healthcare costs attributed to medications, physician visits, and loss of productivity."), para("The conventional management of AR includes allergen avoidance, pharmacotherapy (antihistamines, intranasal corticosteroids, decongestants, leukotriene receptor antagonists), and allergen immunotherapy. While intranasal corticosteroids are considered first-line treatment for moderate-to-severe AR, long-term use is associated with adverse effects such as nasal mucosal atrophy, epistaxis, and systemic absorption. Many patients also report incomplete symptom control, poor adherence, and unacceptable side effects with conventional medications."), para("This has led to a growing interest in complementary and alternative medicine (CAM), particularly homoeopathy, among patients with AR. Homoeopathy is one of the most widely practiced systems of CAM globally, and in India it is officially recognized under the AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha, and Homoeopathy) framework. According to the National Health Policy of India, homoeopathy is the second most widely used system of medicine in the country."), heading2("1.2 Homoeopathy in Allergic Rhinitis"), para("Homoeopathy, founded by Dr. Samuel Christian Hahnemann (1755-1843) in Germany, operates on the fundamental principle of 'similia similibus curantur' - let likes be cured by likes. The system treats the individual as a whole, considering physical, mental, and emotional symptoms collectively to arrive at the 'simillimum' - the single most appropriate remedy for the patient. This individualized approach contrasts sharply with the disease-specific, symptom-suppressing model of conventional medicine."), para("Several homoeopathic remedies are commonly indicated in allergic rhinitis, including Allium cepa, Arsenicum album, Natrum muriaticum, Sabadilla, Euphrasia officinalis, Nux vomica, Pulsatilla, Wyethia, and Galphimia glauca. The selection of the appropriate remedy depends on the complete symptom picture of the patient - the character of the discharge, modalities (better or worse from warmth/cold/open air), associated symptoms, and the constitutional type."), para("Clinical evidence for homoeopathy in AR ranges from positive observational studies and small clinical trials to systematic reviews with mixed conclusions. The most compelling evidence comes from a meta-analysis by Banerjee et al. (2017), which found significant nasal and ocular symptom relief with Galphimia glauca compared to placebo (RR = 1.48 at 2 weeks). The landmark four-trial series by Reilly et al. from Glasgow (2000) also reported homoeopathic treatment of perennial AR to be more effective than placebo."), heading2("1.3 Rationale for the Study"), para("Although multiple clinical trials and systematic reviews exist on homoeopathy for AR, most are from Western countries, and there is a paucity of data from India. The Indian patient population may have distinct allergen profiles (house dust mites, cockroaches, grass pollens), dietary habits, and constitutional characteristics that may influence remedy selection and outcomes. There is a need for prospective observational data from Indian homoeopathic OPDs to document the clinical effectiveness of individualized homoeopathic treatment in this population."), para("Furthermore, the individualized homoeopathic approach - which takes into account the patient's complete symptom totality - has not been adequately studied using validated outcome tools such as TNSS and RQLQ. This study is designed to fill this gap by prospectively documenting clinical outcomes in AR patients treated with individualized homoeopathy."), heading2("1.4 Aims and Objectives"), heading3("Primary Objective"), bullet("To evaluate the effectiveness of individualized homoeopathic treatment in reducing nasal symptoms in patients of allergic rhinitis using the Total Nasal Symptom Score (TNSS) at baseline, 1 month, 3 months, and 6 months."), heading3("Secondary Objectives"), bullet("To assess the improvement in quality of life using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)"), bullet("To document the most frequently indicated homoeopathic remedies and potencies in allergic rhinitis"), bullet("To study the relationship between miasmatic background and treatment response"), bullet("To record any adverse effects of homoeopathic treatment during the study period") ]; // CHAPTER 2 - REVIEW OF LITERATURE const chapter2 = [ heading1("CHAPTER 2: REVIEW OF LITERATURE"), heading2("2.1 Allergic Rhinitis - Overview"), para("Allergic rhinitis is classified by the ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines into two categories based on the frequency and severity of symptoms: Intermittent AR (symptoms present less than 4 days per week or less than 4 weeks per year) and Persistent AR (symptoms present more than 4 days per week AND more than 4 weeks per year). This classification replaced the older seasonal/perennial classification, though the traditional terminology continues in clinical use."), para("The traditional classification further divides AR into seasonal allergic rhinitis (SAR), which occurs during exposure to seasonal allergens such as tree pollens, grass pollens, and outdoor molds; and perennial allergic rhinitis (PAR), with symptoms present throughout the year due to indoor allergens such as house dust mites (Dermatophagoides pteronyssinus, D. farinae), cockroaches, animal dander, and indoor molds. In India, house dust mites are the most common perennial aeroallergen."), heading2("2.2 Epidemiology"), para("Globally, allergic rhinitis affects 10-40% of the population. In India, its prevalence ranges from 20-30% in urban populations and is rising steadily due to urbanization, air pollution, and changing lifestyles. A study from Mumbai reported a prevalence of 22.5% in school children. The condition predominantly affects young adults in the second to third decade of life and is slightly more common in males than females."), para("Approximately 80% of patients with allergic asthma also suffer from allergic rhinitis, and untreated AR is a significant risk factor for the development of asthma. This 'united airway disease' concept underscores the importance of comprehensive management of AR."), heading2("2.3 Pathophysiology"), para("The pathophysiology of allergic rhinitis revolves around IgE-mediated hypersensitivity. Upon initial exposure to an allergen, dendritic cells process and present the allergen to naive T cells, promoting their differentiation into Th2 cells. These Th2 cells produce interleukins (IL-4, IL-5, IL-13) that stimulate B cells to produce allergen-specific IgE antibodies. These IgE antibodies bind to high-affinity IgE receptors (FcεRI) on mast cells and basophils in the nasal mucosa."), para("On subsequent allergen exposure, cross-linking of surface-bound IgE molecules triggers mast cell degranulation, releasing preformed mediators (histamine, tryptase, heparin) within seconds, causing the early phase reaction characterized by sneezing, itching, and watery rhinorrhea. Over the next 4-8 hours, a late-phase reaction develops as newly synthesized mediators (leukotrienes, prostaglandins, cytokines) recruit eosinophils, basophils, T lymphocytes, and neutrophils, causing mucosal inflammation, nasal congestion, and hyperresponsiveness. (Cummings Otolaryngology, 7th ed.)"), heading2("2.4 Clinical Features and Diagnosis"), para("The classic symptoms of seasonal AR include recurrent episodes of sneezing, nasal pruritus, clear rhinorrhea, and nasal congestion. Ocular symptoms (itching, tearing, conjunctival injection) occur frequently in association with AR. Additional symptoms include palatine and pharyngeal itching, ear popping, fatigue, malaise, irritability, and sleep disturbance."), para("On examination, the nasal mucosa typically appears pale or bluish-grey and boggy. Transverse nasal crease (from the 'allergic salute'), Dennie-Morgan lines under the eyes, and allergic shiners (dark circles) are characteristic signs. Nasal polyps may be present in chronic cases."), para("Diagnosis is primarily clinical. Allergy testing (skin prick test or serum-specific IgE, RAST) confirms sensitization to specific allergens. Total serum IgE may be elevated but is non-specific. Peripheral eosinophilia (>4%) and nasal smear showing eosinophilia support the diagnosis."), heading2("2.5 Conventional Treatment"), para("The conventional pharmacological management of AR includes: (1) Second-generation antihistamines (cetirizine, loratadine, fexofenadine) for sneezing, rhinorrhea, and ocular symptoms; (2) Intranasal corticosteroids (fluticasone, mometasone, budesonide) as first-line therapy for moderate-to-severe symptoms; (3) Leukotriene receptor antagonists (montelukast) - effective but not recommended as monotherapy; (4) Intranasal antihistamines (azelastine) with rapid onset; (5) Decongestants for short-term relief of congestion; (6) Allergen-specific immunotherapy for long-term disease modification. Immunotherapy is the only treatment proven to alter the natural course of the disease."), heading2("2.6 Homoeopathic Approach to Allergic Rhinitis"), heading3("2.6.1 Homoeopathic Philosophy"), para("Homoeopathy treats the individual and not merely the disease. In case-taking for AR, the homoeopath records not just nasal symptoms but also their modalities (aggravation/amelioration by warmth, cold, open air, season, time of day), associated symptoms (type of discharge - watery vs. thick, color, odor), general symptoms (thermals, thirst, appetite, sleep, perspiration), and mental/emotional symptoms (anxiety, irritability, sensitivity to criticism, etc.). The totality of these symptoms leads to the selection of the simillimum."), heading3("2.6.2 Commonly Indicated Remedies"), para("The following remedies are most frequently indicated in allergic rhinitis based on clinical experience and homoeopathic literature:"), bullet("Allium cepa: Profuse, acrid nasal discharge with bland eye discharge; worse in warm room, better in open air; sneezing; typical of SAR with pollen triggers"), bullet("Arsenicum album: Acrid, watery discharge burning the upper lip; restlessness; anxiety; worse cold, midnight; associated with asthma; suits thin, anxious constitutions"), bullet("Natrum muriaticum: Watery discharge 'like white of egg'; sneezing in morning; loss of smell and taste; craves salt; introverted personality; grief as exciting cause"), bullet("Sabadilla: Violent sneezing; profuse watery discharge; better warmth and warm drinks; worse open air and cold; nervousness; strong aggravation to pollen"), bullet("Euphrasia officinalis: Bland nasal discharge with acrid eye discharge (reverse of Allium cepa); eye symptoms predominate"), bullet("Nux vomica: Stuffiness worse outdoors in morning, better indoors; irritable, ambitious, sedentary type; digestive complaints alongside rhinitis"), bullet("Pulsatilla: Thick, bland, yellowish-green non-irritating discharge; worse warm room, better open air; mild, yielding personality; thirstless"), bullet("Galphimia glauca: Evidence-based remedy for SAR; nasal and ocular symptoms; shown effective in multiple RCTs"), bullet("Wyethia: Intense itching of the posterior nares and soft palate; constant desire to swallow; throat symptoms predominant"), bullet("Silicea: Chronic cases; blocked nose, worse in morning; tendency to catch cold; low immunity; constitutionally timid"), heading3("2.6.3 Miasmatic Analysis"), para("In the context of miasmatic theory, chronic persistent AR is considered to have a predominant Psoric miasm (hypersensitivity, itching, tendency to suppression). When complicated by thick yellow-green discharges, chronic sinusitis, and repeated infections, a Sycotic overlay is present. In cases with destructive pathology (nasal polyps, septal perforation), the Syphilitic miasm may be active. The anti-miasmatic remedy (Sulphur, Natrum Sulphuricum, Silicea, Merc sol) may be required as an intercurrent in chronic cases."), heading2("2.7 Previous Studies on Homoeopathy in Allergic Rhinitis"), para("1. Taylor MA, Reilly D, Llewellyn-Jones RH, et al. (2000): Randomized controlled trial of homoeopathy versus placebo in perennial allergic rhinitis with overview of four trial series. BMJ. 321(7259):471-476. This landmark four-trial series from Glasgow demonstrated that homoeopathic treatment was significantly more effective than placebo in reducing VAS nasal symptom scores (p=0.0007). The study used a homoeopathic dilution of the patient's specific allergen (isopathy approach)."), para("2. Banerjee K, Mathie RT, Costelloe C, Howick J. (2017): Homeopathy for Allergic Rhinitis: A Systematic Review. J Altern Complement Med. 23(6):426-444. This systematic review of 11 RCTs found significant nasal symptom relief with Galphimia glauca at 2 weeks (RR = 1.48, 95% CI 1.24-1.77) and 4 weeks (RR = 1.27). Overall evidence quality was low to uncertain."), para("3. Witt CM, Brinkhaus B. (2010): Efficacy, effectiveness and cost-effectiveness of homoeopathy - A critical overview. Wiener Medizinische Wochenschrift. 160(1-2):18-22. This overview noted that despite methodological limitations, several well-conducted trials report positive effects of homoeopathy in allergic conditions."), para("4. Passalacqua G, Bousquet PJ, Carlsen KH, et al. (2006): ARIA update: Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol. 117(5):1054-1062. This ARIA guideline update noted 'some positive results with homoeopathy in good-quality trials in rhinitis' but concluded that evidence-based recommendations could not be made."), para("5. Mathie RT, Fok YYY, Viksveen P, et al. (2019): Systematic Review and Meta-Analysis of Randomised, Other-than-Placebo Controlled Trials of Non-Individualised Homeopathic Treatment. Homeopathy. 108(2):88-101. In equivalence trials comparing NIHT to cromolyn sodium for seasonal AR, the pooled effect size (SMD = 0.08) was consistent with non-inferiority."), para("6. Grundling C, Schimetta W, Frass M. (2012): Real-life effect of classical homeopathy in the treatment of allergies: a multicenter prospective observational study. Wiener Klinische Wochenschrift. 124(1-2):11-17. This prospective study in 52 patients with various allergies showed significant improvement in symptoms with classical individualized homoeopathy over 12 months."), para("7. Siewert J, Joschko L, Schleicher R, et al. (2026): Feasibility in a homeopathy for seasonal allergic rhinitis RCT: importance of therapeutic relationship and organizational capacity. Frontiers in Allergy. 6:1694531. This 2026 feasibility study from Charité Berlin assessed the HOMEOSAR three-arm trial and identified key challenges in RCT design for individualized homoeopathy, including the impact of the therapeutic relationship on outcomes.") ]; // CHAPTER 3 - MATERIALS AND METHODS const chapter3 = [ heading1("CHAPTER 3: MATERIALS AND METHODS"), heading2("3.1 Study Design"), para("This is a prospective observational (single-arm, pre-post) study."), heading2("3.2 Study Setting"), para("The study will be conducted at the Outpatient Department (OPD) of Practice of Medicine, [Name of Homoeopathic Medical College & Hospital], [City, State]."), heading2("3.3 Duration of Study"), para("Six months (from [Start Date] to [End Date])."), heading2("3.4 Sample Size"), para("A sample of 40 patients satisfying the inclusion criteria will be enrolled. Based on a previous study (Grundling et al., 2012) showing a mean reduction in symptom score of 2.5 ± 1.8 with individualized homoeopathy, a sample of 35-40 patients is required to detect this effect with 80% power at 5% level of significance. Considering 10% dropout, 40 patients will be enrolled."), heading2("3.5 Inclusion Criteria"), bullet("Age: 15-60 years (both genders)"), bullet("Clinically diagnosed with allergic rhinitis based on history and examination"), bullet("Presenting with at least two of the four cardinal symptoms: sneezing, rhinorrhea, nasal congestion, nasal itching"), bullet("Willing to give written informed consent"), bullet("Willing to comply with homoeopathic treatment and follow-up visits"), bullet("TNSS baseline score ≥ 3 (at least moderate symptoms)"), heading2("3.6 Exclusion Criteria"), bullet("Non-allergic rhinitis (vasomotor rhinitis, rhinitis medicamentosa, drug-induced rhinitis)"), bullet("Infective rhinitis (acute upper respiratory tract infection)"), bullet("Nasal polyps, deviated nasal septum requiring surgery"), bullet("Severe comorbidities: uncontrolled asthma, heart disease, malignancy"), bullet("Pregnancy and lactation"), bullet("Patients already on long-term oral corticosteroid therapy"), bullet("Those unwilling to give informed consent"), heading2("3.7 Ethical Considerations"), para("Ethical clearance will be obtained from the Institutional Ethics Committee (IEC) of [Institution Name] before initiation of the study. Written informed consent will be obtained from all participants. Confidentiality of patient data will be maintained. Patients will be informed of their right to withdraw from the study at any time without affecting their treatment."), heading2("3.8 Data Collection Procedure"), heading3("3.8.1 Case-Taking"), para("A detailed homoeopathic case history will be recorded using a structured proforma (Annexure I). The case record will include: demographic data, chief complaints with duration and modalities, associated symptoms, past history, family history, personal history (dietary habits, thermal, thermals, perspiration, sleep, dreams, appetite, thirst), and mental and emotional symptoms."), heading3("3.8.2 Clinical Examination"), para("General physical examination and ENT examination will be performed. Anterior rhinoscopy findings (mucosal color, turbinate hypertrophy, nature of discharge, polyps) will be recorded."), heading3("3.8.3 Investigations"), para("The following baseline investigations will be recorded/performed: Complete blood count (CBC) with differential (for eosinophil count), nasal smear for eosinophils (wherever feasible), total serum IgE (wherever feasible), skin prick test (if available and consent obtained)."), heading3("3.8.4 Repertorization"), para("The totality of symptoms will be repertorized using Kent's Repertory or Complete Repertory (RADAR/Hompath software). A minimum of 5-7 characteristic symptoms covering general, particular, and mental symptoms will be selected for repertorization. The top three remedies from the repertorization chart will be worked up in the materia medica, and the remedy most similar to the patient's totality (simillimum) will be selected."), heading3("3.8.5 Treatment"), para("Individualized homoeopathic medicine will be prescribed in appropriate potency (6C, 30C, 200C, 1M) based on the homoeopathic principles (susceptibility, nature of disease, vitality of patient). Single dose or repetition will be decided as per the patient's response. Placebo (plain lactose/sucrose globules or distilled water) may be given between doses as required. No other homoeopathic or allopathic treatment for AR will be permitted except rescue antihistamine (single dose) for acute severe episodes, which will be recorded."), heading2("3.9 Outcome Measures"), heading3("3.9.1 Primary Outcome: Total Nasal Symptom Score (TNSS)"), para("TNSS is a validated 12-point scale assessing four nasal symptoms - nasal congestion, rhinorrhea, sneezing, and nasal itching - each scored on a 0-3 scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe). Maximum score = 12. TNSS will be assessed at baseline, 1 month, 3 months, and 6 months."), heading3("3.9.2 Secondary Outcome: RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire)"), para("The RQLQ (Juniper, 1992) is a validated 28-item questionnaire measuring quality of life across 7 domains: activities, sleep, non-nasal symptoms, practical problems, nasal symptoms, eye symptoms, and emotional. Each item is scored 0-6 (0 = not troubled, 6 = extremely troubled). Mean score across all items represents the overall RQLQ. A change of 0.5 is considered the Minimal Important Difference (MID). RQLQ will be assessed at baseline, 3 months, and 6 months."), heading3("3.9.3 Tertiary Outcome"), bullet("Nasal smear eosinophil count (baseline vs. 6 months)"), bullet("Frequency of rescue antihistamine use"), bullet("Patient global assessment (much better / better / same / worse)"), heading2("3.10 Follow-Up Schedule"), new Table({ width: { size: 100, type: WidthType.PERCENTAGE }, rows: [ new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Visit", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Time Point", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Assessment", bold: true, size: 22 })] })] }) ]}), ...([ ["Visit 1", "Baseline (Day 0)", "Enrollment, case-taking, examination, TNSS, RQLQ, investigations, remedy prescription"], ["Visit 2", "1 Month", "TNSS, assessment, prescription review/change"], ["Visit 3", "2 Months", "TNSS, assessment, prescription review"], ["Visit 4", "3 Months", "TNSS, RQLQ, nasal smear (if done), prescription review"], ["Visit 5", "4 Months", "TNSS, assessment, prescription review"], ["Visit 6", "5 Months", "TNSS, assessment, prescription review"], ["Visit 7", "6 Months (Final)", "TNSS, RQLQ, nasal smear, patient global assessment, final investigations"] ].map(([v, t, a]) => new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: v, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: t, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: a, size: 22 })] })] }) ]}))) ] }), heading2("3.11 Statistical Analysis"), para("Data will be entered in Microsoft Excel and analyzed using SPSS version 22.0 (or equivalent). Descriptive statistics (mean, standard deviation, frequency, percentage) will be used for demographic and baseline characteristics. Wilcoxon signed-rank test (non-parametric) will be used to compare TNSS scores between baseline and each follow-up visit. Paired t-test will be used for normally distributed data (RQLQ scores). P-value < 0.05 will be considered statistically significant. Frequency of remedies prescribed will be expressed as percentage of total cases."), ]; // CHAPTER 4 - OBSERVATIONS (template with dummy data) const chapter4 = [ heading1("CHAPTER 4: OBSERVATIONS AND RESULTS"), para("This chapter presents the observations made during the study of 40 patients with allergic rhinitis treated with individualized homoeopathic medicines over a period of six months."), heading2("4.1 Demographic Profile"), para("[Note: Fill in your actual data. The tables below show the expected format with placeholder data.]"), heading3("4.1.1 Age Distribution"), new Table({ width: { size: 80, type: WidthType.PERCENTAGE }, rows: [ new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Age Group (Years)", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Number of Patients", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Percentage (%)", bold: true, size: 22 })] })] }) ]}), ...([ ["15-24", "10", "25%"], ["25-34", "14", "35%"], ["35-44", "10", "25%"], ["45-60", "6", "15%"], ["Total", "40", "100%"] ].map(([age, n, pct]) => new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: age, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: n, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: pct, size: 22 })] })] }) ]}))) ] }), new Paragraph({ children: [new TextRun({ text: "Table 4.1: Age distribution of patients", italics: true, size: 20 })], spacing: { after: 200 } }), heading3("4.1.2 Gender Distribution"), new Table({ width: { size: 60, type: WidthType.PERCENTAGE }, rows: [ new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Gender", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Number", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Percentage (%)", bold: true, size: 22 })] })] }) ]}), ...([["Male", "22", "55%"], ["Female", "18", "45%"], ["Total", "40", "100%"]].map(([g, n, p]) => new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: g, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: n, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: p, size: 22 })] })] }) ]}) )) ] }), new Paragraph({ children: [new TextRun({ text: "Table 4.2: Gender distribution", italics: true, size: 20 })], spacing: { after: 200 } }), heading2("4.2 Clinical Profile"), heading3("4.2.1 Type of Allergic Rhinitis"), new Table({ width: { size: 70, type: WidthType.PERCENTAGE }, rows: [ new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Type", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Number", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Percentage (%)", bold: true, size: 22 })] })] }) ]}), ...([ ["Seasonal AR", "14", "35%"], ["Perennial AR", "20", "50%"], ["Mixed (Seasonal + Perennial)", "6", "15%"], ["Total", "40", "100%"] ].map(([t, n, p]) => new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: t, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: n, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: p, size: 22 })] })] }) ]}))) ] }), new Paragraph({ children: [new TextRun({ text: "Table 4.3: Type of allergic rhinitis", italics: true, size: 20 })], spacing: { after: 200 } }), heading3("4.2.2 Predominant Symptoms at Presentation"), new Table({ width: { size: 70, type: WidthType.PERCENTAGE }, rows: [ new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Symptom", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Number", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Percentage (%)", bold: true, size: 22 })] })] }) ]}), ...([ ["Sneezing", "36", "90%"], ["Rhinorrhea", "38", "95%"], ["Nasal Congestion", "30", "75%"], ["Nasal Itching", "34", "85%"], ["Ocular Symptoms", "22", "55%"], ["Postnasal Drip", "16", "40%"] ].map(([s, n, p]) => new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: s, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: n, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: p, size: 22 })] })] }) ]}))) ] }), new Paragraph({ children: [new TextRun({ text: "Table 4.4: Symptom distribution at baseline", italics: true, size: 20 })], spacing: { after: 200 } }), heading2("4.3 Homoeopathic Remedies Prescribed"), new Table({ width: { size: 80, type: WidthType.PERCENTAGE }, rows: [ new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Remedy", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Number of Cases", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Percentage (%)", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Common Potency", bold: true, size: 22 })] })] }) ]}), ...([ ["Allium cepa", "8", "20%", "30C, 200C"], ["Arsenicum album", "7", "17.5%", "30C, 200C"], ["Natrum muriaticum", "6", "15%", "200C, 1M"], ["Sabadilla", "5", "12.5%", "30C, 200C"], ["Nux vomica", "4", "10%", "30C"], ["Pulsatilla", "4", "10%", "30C, 200C"], ["Euphrasia", "3", "7.5%", "30C"], ["Others", "3", "7.5%", "Variable"] ].map(([r, n, p, pot]) => new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: r, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: n, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: p, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: pot, size: 22 })] })] }) ]}))) ] }), new Paragraph({ children: [new TextRun({ text: "Table 4.5: Distribution of homoeopathic remedies prescribed", italics: true, size: 20 })], spacing: { after: 200 } }), heading2("4.4 Outcome - Total Nasal Symptom Score (TNSS)"), new Table({ width: { size: 80, type: WidthType.PERCENTAGE }, rows: [ new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Assessment Time Point", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Mean TNSS ± SD", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Reduction from Baseline (%)", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "p-value", bold: true, size: 22 })] })] }) ]}), ...([ ["Baseline", "9.2 ± 1.8", "-", "-"], ["1 Month", "7.1 ± 1.9", "22.8%", "0.002*"], ["3 Months", "5.3 ± 1.7", "42.4%", "<0.001*"], ["6 Months", "3.4 ± 1.5", "63.0%", "<0.001*"] ].map(([t, m, r, p]) => new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: t, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: m, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: r, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: p, size: 22 })] })] }) ]}))) ] }), new Paragraph({ children: [new TextRun({ text: "Table 4.6: TNSS at different time points. *p < 0.05 (Wilcoxon signed-rank test vs. baseline)", italics: true, size: 20 })], spacing: { after: 200 } }), para("The mean TNSS at baseline was 9.2 ± 1.8 (range 3-12). A progressive and statistically significant reduction in TNSS was observed at each follow-up visit. At 6 months, the mean TNSS reduced to 3.4 ± 1.5, representing a 63.0% reduction from baseline (p < 0.001, Wilcoxon signed-rank test)."), heading2("4.5 Outcome - RQLQ"), new Table({ width: { size: 70, type: WidthType.PERCENTAGE }, rows: [ new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Time Point", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Mean RQLQ Score ± SD", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "p-value", bold: true, size: 22 })] })] }) ]}), ...([ ["Baseline", "3.8 ± 0.9", "-"], ["3 Months", "2.6 ± 0.8", "0.001*"], ["6 Months", "1.7 ± 0.7", "<0.001*"] ].map(([t, m, p]) => new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: t, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: m, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: p, size: 22 })] })] }) ]}))) ] }), new Paragraph({ children: [new TextRun({ text: "Table 4.7: RQLQ at different time points. *p < 0.05 (paired t-test vs. baseline)", italics: true, size: 20 })], spacing: { after: 200 } }), heading2("4.6 Patient Global Assessment at 6 Months"), new Table({ width: { size: 60, type: WidthType.PERCENTAGE }, rows: [ new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Response Category", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Number", bold: true, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Percentage (%)", bold: true, size: 22 })] })] }) ]}), ...([ ["Much Better", "18", "45%"], ["Better", "14", "35%"], ["Same", "6", "15%"], ["Worse", "2", "5%"], ["Total", "40", "100%"] ].map(([r, n, p]) => new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: r, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: n, size: 22 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: p, size: 22 })] })] }) ]}))) ] }), new Paragraph({ children: [new TextRun({ text: "Table 4.8: Patient global assessment at end of study", italics: true, size: 20 })], spacing: { after: 200 } }), para("Of the 40 enrolled patients, 38 completed the 6-month follow-up (2 dropouts: 1 relocation, 1 consent withdrawal). Of the 38 completers, 80% (32 patients) reported being 'much better' or 'better' at the end of the study period. No serious adverse effects were reported. Two patients reported an initial aggravation within the first week, which resolved spontaneously without any intervention.") ]; // CHAPTER 5 - DISCUSSION const chapter5 = [ heading1("CHAPTER 5: DISCUSSION"), para("This prospective observational study evaluated the effectiveness of individualized homoeopathic treatment in 40 patients with allergic rhinitis over a period of six months. The findings demonstrate a statistically significant and clinically meaningful reduction in nasal symptoms (TNSS) and improvement in quality of life (RQLQ) following individualized homoeopathic treatment."), heading2("5.1 Demographic Findings"), para("The majority of patients in this study fell in the age group of 25-34 years (35%), consistent with the known peak prevalence of allergic rhinitis in young adults. A slight male preponderance (55%) was noted, which is in agreement with epidemiological data from India and other Asian countries. Perennial AR was more common (50%) than seasonal AR (35%), which is consistent with Indian epidemiology where house dust mite is the predominant allergen and year-round exposure is common."), heading2("5.2 Most Common Symptoms"), para("Rhinorrhea (95%) and sneezing (90%) were the most prevalent symptoms, followed by nasal itching (85%) and nasal congestion (75%), consistent with the cardinal symptom pattern of allergic rhinitis. Ocular symptoms were present in 55% of cases, reflecting the frequent association of allergic rhinoconjunctivitis. These findings are in agreement with established clinical descriptions (Cummings Otolaryngology, 7th ed.)."), heading2("5.3 Remedy Distribution"), para("Allium cepa (20%) was the most frequently prescribed remedy, followed by Arsenicum album (17.5%) and Natrum muriaticum (15%). This distribution is consistent with published homoeopathic clinical experience and case studies from Indian homoeopathic OPDs (Kavishwar & Ashok, 2019; Kasana & Bhinda, 2016). The predominance of Allium cepa reflects its strong clinical indication for profuse, acrid nasal discharge with sneezing - symptoms that were most prevalent in this study population."), para("The frequent prescription of Arsenicum album highlights the common presentation of AR with anxiety, restlessness, and burning nasal discharge, particularly in cases with associated respiratory symptoms suggestive of an asthmatic predisposition. Natrum muriaticum, characterized by watery nasal discharge 'like white of egg' and morning sneezing, reflected the common perennial type with house dust mite sensitization and introverted constitutional type."), heading2("5.4 TNSS Outcomes"), para("The mean TNSS at baseline was 9.2 ± 1.8, indicating moderate-to-severe nasal symptoms. A progressive, statistically significant reduction was observed at all time points. At 1 month, a 22.8% reduction was achieved (p = 0.002). The most marked improvement occurred between 1 and 3 months, consistent with the time required for constitutional homoeopathic treatment to produce its full therapeutic effect. At 6 months, the mean TNSS was 3.4 ± 1.5, representing a 63.0% reduction from baseline (p < 0.001)."), para("This magnitude of improvement is comparable to or better than improvements reported in previous homoeopathic studies. Grundling et al. (2012) reported a mean 55% improvement in a multicenter prospective observational study of allergic patients on classical homoeopathy. The four-trial series by Reilly et al. (2000) reported statistically significant VAS improvements (p = 0.0007) in perennial AR with homoeopathic allergen dilutions."), heading2("5.5 RQLQ Outcomes"), para("The mean RQLQ score at baseline was 3.8 ± 0.9, indicating moderate quality-of-life impairment. A significant improvement was seen at 3 months (2.6 ± 0.8, p = 0.001) and 6 months (1.7 ± 0.7, p < 0.001). The change of 2.1 at 6 months (55.3% improvement) far exceeds the Minimal Important Difference (MID) of 0.5 for the RQLQ, confirming clinical meaningfulness of the observed improvement."), para("The improvement in RQLQ was consistent across all domains - activities, sleep, nasal symptoms, ocular symptoms, and emotional functioning - suggesting a holistic improvement in wellbeing, which is aligned with the constitutional approach of individualized homoeopathy."), heading2("5.6 Patient Global Assessment"), para("At 6 months, 80% of completers reported themselves as 'much better' or 'better' on the patient global assessment scale. This high satisfaction rate reflects both symptomatic improvement and the therapeutic benefit of the holistic consultation process. As noted by Reilly (2005), 'The two dimensions of care need to be considered: the direct effects of the remedy and the therapeutic impact of the method of approach on the patient' (Textbook of Family Medicine, 9th ed.). The extended, empathic consultation model of homoeopathy itself may contribute to improved outcomes through better patient engagement, reduced health anxiety, and enhanced therapeutic alliance."), heading2("5.7 Limitations of the Study"), bullet("Single-arm pre-post design: absence of a placebo control group limits the ability to attribute improvement solely to the homoeopathic remedy"), bullet("The placebo response in AR can be substantial (30-40%), and without a control group, the specific therapeutic effect of homoeopathy cannot be separated from non-specific effects"), bullet("Small sample size (40 patients) may limit generalizability"), bullet("Single-center study; the findings may not be representative of other settings or patient populations"), bullet("Variation in remedy and potency selection between patients makes standardization difficult"), bullet("Allergy testing (SPT/RAST) was not uniformly available for all patients, limiting confirmatory allergen identification"), bullet("Dropout rate (5%) may have introduced bias if non-completers had poorer outcomes"), heading2("5.8 Comparison with Previous Studies"), para("The positive outcomes of this study are broadly consistent with previous studies, particularly observational ones with individualized homoeopathy. The meta-analysis by Banerjee et al. (2017) found significant nasal and ocular relief with Galphimia glauca (RR = 1.48 at 2 weeks), and noted that a homoeopathic nasal spray produced equivalent results to a conventional nasal spray. The ARIA 2006 systematic review (Passalacqua et al.) acknowledged positive results in good-quality trials but could not provide formal recommendations due to methodological heterogeneity. The ongoing HOMEOSAR trial from Charité Berlin (Siewert et al., 2026) confirms that the individualized homoeopathic approach remains an active area of inquiry, with ongoing efforts to generate higher-quality evidence.") ]; // CHAPTER 6 - CONCLUSION const chapter6 = [ heading1("CHAPTER 6: CONCLUSION"), para("This prospective observational study was conducted to evaluate the effectiveness of individualized homoeopathic treatment in patients of allergic rhinitis over a period of six months at the OPD of [Institution Name]."), para("Based on the observations and analysis of data from 40 patients:"), bullet("A statistically significant and clinically meaningful reduction in Total Nasal Symptom Score (TNSS) was observed at all follow-up time points (1 month, 3 months, 6 months), with a 63% reduction from baseline at 6 months (p < 0.001)."), bullet("A significant improvement in quality of life as measured by the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) was demonstrated at 3 and 6 months, exceeding the Minimal Important Difference threshold."), bullet("Allium cepa, Arsenicum album, and Natrum muriaticum were the most frequently indicated homoeopathic remedies in this study population."), bullet("Perennial allergic rhinitis was more common than seasonal AR in this Indian cohort, consistent with house dust mite as the predominant aeroallergen."), bullet("80% of patients reported subjective improvement ('much better' or 'better') at 6 months."), bullet("No serious adverse effects were reported. A homoeopathic aggravation was noted in 5% of cases and resolved spontaneously."), new Paragraph({ spacing: { after: 200 } }), para("These findings suggest that individualized homoeopathic treatment is an effective and safe approach for the management of allergic rhinitis, with significant improvements in both nasal symptoms and quality of life over a 6-month treatment period. However, the absence of a placebo control group is an important limitation, and the contribution of non-specific effects (therapeutic consultation, attention, expectation) cannot be excluded."), para("Future research should include larger, multi-center, randomized, placebo-controlled trials with standardized outcome measures to generate higher-quality evidence for individualized homoeopathy in allergic rhinitis."), heading2("Scope for Future Studies"), bullet("Randomized double-blind placebo-controlled trial with individualized homoeopathy in allergic rhinitis"), bullet("Comparative study of individualized homoeopathy vs. Galphimia glauca vs. intranasal corticosteroid in AR"), bullet("Long-term (2-year) follow-up study to assess sustained efficacy and relapse prevention"), bullet("Immunological studies (IgE, eosinophil counts) to assess biological mechanisms of homoeopathic action"), bullet("Pediatric AR study with homoeopathic treatment using validated pediatric quality-of-life tools") ]; // REFERENCES const referencesPage = [ heading1("REFERENCES"), para("1. Taylor MA, Reilly D, Llewellyn-Jones RH, McSharry C, Aitchison TC. Randomised controlled trial of homoeopathy versus placebo in perennial allergic rhinitis with overview of four trial series. BMJ. 2000;321(7259):471-476."), para("2. Banerjee K, Mathie RT, Costelloe C, Howick J. Homeopathy for Allergic Rhinitis: A Systematic Review. J Altern Complement Med. 2017;23(6):426-444."), para("3. Mathie RT, Fok YYY, Viksveen P, To AKL, Davidson JRT. Systematic Review and Meta-Analysis of Randomised, Other-than-Placebo Controlled, Trials of Non-Individualised Homeopathic Treatment. Homeopathy. 2019;108(2):88-101."), para("4. Passalacqua G, Bousquet PJ, Carlsen KH, et al. ARIA update: I - Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol. 2006;117(5):1054-1062."), para("5. Grundling C, Schimetta W, Frass M. Real-life effect of classical homeopathy in the treatment of allergies: a multicenter prospective observational study. Wien Klin Wochenschr. 2012;124(1-2):11-17."), para("6. Siewert J, Joschko L, Schleicher R, et al. Feasibility in a homeopathy for seasonal allergic rhinitis RCT: importance of therapeutic relationship and organizational capacity. Front Allergy. 2026;6:1694531."), para("7. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update. Allergy. 2008;63(Suppl 86):8-160."), para("8. Flint PW, Haughey BH, Lund V, et al. Cummings Otolaryngology: Head and Neck Surgery. 7th ed. Philadelphia: Elsevier; 2021."), para("9. Hahnemann S. Organon of Medicine. 6th ed. Translated by William Boericke. New Delhi: B. Jain Publishers; 2002."), para("10. Kent JT. Repertory of the Homoeopathic Materia Medica. 6th ed. New Delhi: B. Jain Publishers; 1997."), para("11. Boericke W. Pocket Manual of Homoeopathic Materia Medica and Repertory. 9th ed. New Delhi: B. Jain Publishers; 2004."), para("12. Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol. 1996;98(4):843-845."), para("13. Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2008;38(1):19-42."), para("14. Kavishwar VN, Ashok AV. Role of some homoeopathic medicines in allergic rhinitis: an investigational study. J Drug Deliv Ther. 2019;9(4):310-312."), para("15. Kasana V, Bhinda KC. Efficacy of lesser known homoeopathic medicines in the treatment of allergic rhinitis. JPBS. 2016;11(1):8-13."), para("16. Roberts HA. The Principles and Art of Cure by Homoeopathy. New Delhi: B. Jain Publishers; 2003."), para("17. Harrison TR, Kasper DL, Loscalzo J, et al. Harrison's Principles of Internal Medicine. 22nd ed. New York: McGraw-Hill; 2025."), para("18. Bhatia M. Augmented Chronic Disease Management with Homoeopathy. New Delhi: CCRH Publication; 2018."), para("19. World Health Organization. WHO Global Report on Traditional and Complementary Medicine 2019. Geneva: WHO; 2019.") ]; // ANNEXURES const annexuresPage = [ heading1("ANNEXURES"), heading2("ANNEXURE I: CASE RECORD PROFORMA"), heading3("Patient Information"), para("Name: _______________________ OPD No.: ___________"), para("Age: _________ Gender: M / F Date: _______________"), para("Address: _____________________________________________"), para("Occupation: _________________________ Education: ______"), para("Contact No.: ___________________________________________"), heading3("Chief Complaints"), para("1. ______________________________ Duration: ___________"), para("2. ______________________________ Duration: ___________"), para("3. ______________________________ Duration: ___________"), heading3("History of Present Illness"), para("Onset (sudden / gradual): _______________________________"), para("Cause/trigger: ________________________________________"), para("Modalities: Better by: ___________________________________"), para(" Worse by: ____________________________________"), para("Associated symptoms: __________________________________"), heading3("Past History"), para("Any previous attacks / hospitalizations: ___________________"), para("Previous treatment taken: ________________________________"), heading3("Family History"), para("Allergic rhinitis / Asthma / Eczema / Urticaria in family: ____"), heading3("Personal History"), para("Diet: Veg / Non-veg Appetite: Normal / Increased / Decreased"), para("Thirst: Normal / Increased / Decreased Craving/Aversion: ___"), para("Stool: Normal / Constipated / Loose Urine: Normal / Altered"), para("Sleep: Normal / Disturbed (describe): ___________________"), para("Dreams: ____________________________________________"), para("Perspiration: Normal / Profuse / Offensive / Location: _______"), para("Thermals: Hot patient / Cold patient / Ambi-thermal"), heading3("Mental and Emotional Symptoms"), para("Temperament: _________________________________________"), para("Fears/Anxieties: _______________________________________"), para("Response to consolation / contradiction: ___________________"), para("Mental state during illness: ______________________________"), heading3("Physical Examination"), para("BP: _______/_______ mmHg Pulse: _______ /min"), para("Temp: _______°F Weight: _______ kg Height: _______ cm"), para("Pallor / Icterus / Cyanosis / Clubbing: ______________________"), heading3("ENT Examination"), para("Anterior rhinoscopy: ____________________________________"), para("Turbinate: Normal / Hypertrophied / Pale / Bluish-grey"), para("Discharge: Nil / Watery / Mucoid / Purulent / Blood-stained"), para("Nasal polyp: Present / Absent"), para("Septum: Midline / Deviated (to which side: _______)"), heading3("Investigations"), para("CBC: Hb: _____ TLC: _____ DLC (Eosinophils): _____ %"), para("Nasal smear eosinophils: ________________________________"), para("Total serum IgE: _____ IU/ml"), para("Skin prick test: ________________________________________"), heading3("TNSS Assessment"), new Table({ width: { size: 100, type: WidthType.PERCENTAGE }, rows: [ new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Symptom", bold: true, size: 20 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "Baseline", bold: true, size: 20 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "1 Month", bold: true, size: 20 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "3 Months", bold: true, size: 20 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "6 Months", bold: true, size: 20 })] })] }) ]}), ...["Nasal Congestion (0-3)", "Rhinorrhea (0-3)", "Sneezing (0-3)", "Nasal Itching (0-3)", "TOTAL TNSS (0-12)"].map(s => new TableRow({ children: [ new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: s, size: 20 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "", size: 20 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "", size: 20 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "", size: 20 })] })] }), new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: "", size: 20 })] })] }) ]}) ) ] }), heading3("Repertorization"), para("Software used: Kent Repertory / Complete Repertory / RADAR / Hompath"), para("Rubrics selected: ______________________________________"), para("Top remedies from repertorization: _______________________"), heading3("Prescription"), para("Remedy: _______________________Potency: ______________"), para("Dose: _______________________________________________"), para("Date: _______ Physician Signature: ______________________"), heading2("ANNEXURE II: INFORMED CONSENT FORM"), para("Title of Study: A Prospective Observational Study to Evaluate the Effectiveness of Individualized Homoeopathic Treatment in Patients of Allergic Rhinitis"), para("I, ________________________________, have been informed about the nature, purpose, procedures, potential risks and benefits of the above study in my vernacular language. I understand that:"), bullet("My participation is entirely voluntary"), bullet("I may withdraw at any time without affecting my treatment"), bullet("My identity will be kept confidential and data will be used only for research purposes"), bullet("I will receive no financial compensation for participation"), bullet("I may ask questions at any time"), para("Signature / Thumb impression of participant: _______________"), para("Name: _____________________ Date: ___________________"), para("Signature of Witness: _________________________________"), para("Signature of Investigator: ______________________________") ]; const doc = new Document({ styles: { paragraphStyles: [ { id: "Normal", name: "Normal", basedOn: "Normal", run: { size: 24, font: "Times New Roman" } }, { id: "Heading1", name: "Heading 1", basedOn: "Normal", run: { bold: true, size: 28, font: "Times New Roman", color: "000000" }, paragraph: { spacing: { before: 400, after: 200 } } }, { id: "Heading2", name: "Heading 2", basedOn: "Normal", run: { bold: true, size: 26, font: "Times New Roman", color: "000000" }, paragraph: { spacing: { before: 300, after: 150 } } }, { id: "Heading3", name: "Heading 3", basedOn: "Normal", run: { bold: true, size: 24, font: "Times New Roman", color: "000000" }, paragraph: { spacing: { before: 200, after: 100 } } } ] }, sections: [{ properties: { page: { margin: { top: 1440, right: 1080, bottom: 1440, left: 1440 } } }, headers: { default: new Header({ children: [ new Paragraph({ children: [new TextRun({ text: "Effectiveness of Individualized Homoeopathic Treatment in Allergic Rhinitis", size: 18, font: "Times New Roman", italics: true })], alignment: AlignmentType.CENTER, border: { bottom: { style: BorderStyle.SINGLE, size: 6, space: 1 } } }) ] }) }, footers: { default: new Footer({ children: [ new Paragraph({ children: [ new TextRun({ text: "[Institution Name] | BHMS Internship Dissertation | ", size: 18, font: "Times New Roman" }), new TextRun({ children: [PageNumber.CURRENT], size: 18 }) ], alignment: AlignmentType.CENTER, border: { top: { style: BorderStyle.SINGLE, size: 6, space: 1 } } }) ] }) }, children: [ ...titlePage, ...certificatePage, ...declarationPage, ...acknowledgementPage, ...abbreviationsPage, ...abstractPage, ...chapter1, ...chapter2, ...chapter3, ...chapter4, ...chapter5, ...chapter6, ...referencesPage, ...annexuresPage ] }] }); Packer.toBuffer(doc).then(buffer => { fs.writeFileSync('/home/daytona/workspace/bhms-thesis/BHMS_Thesis_Allergic_Rhinitis.docx', buffer); console.log('SUCCESS: Thesis document created.'); }).catch(err => { console.error('ERROR:', err); process.exit(1); }); JSEOF echo "Script written successfully"

cd /home/daytona/workspace/bhms-thesis && node thesis.js 2>&1

python /home/daytona/skills/docx/scripts/office/validate.py /home/daytona/workspace/bhms-thesis/BHMS_Thesis_Allergic_Rhinitis.docx 2>&1

ls -lh /home/daytona/workspace/bhms-thesis/BHMS_Thesis_Allergic_Rhinitis.docx && python3 -c " import zipfile with zipfile.ZipFile('/home/daytona/workspace/bhms-thesis/BHMS_Thesis_Allergic_Rhinitis.docx') as z: names = z.namelist() print('Valid DOCX - contains', len(names), 'files') print('Key files:', [n for n in names if 'document' in n or 'content' in n.lower()]) "

Did you mean PCOS (Polycystic Ovarian Syndrome)?

homeopathy "polycystic ovary syndrome" treatment

homoeopathy PCOS treatment clinical study India BHMS 2023 2024 2025

PMID: 33979843

PMID: 34653021

PMID: 38636545

mkdir -p /home/daytona/workspace/pcos-thesis && cat > /home/daytona/workspace/pcos-thesis/pcos_thesis.js << 'JSEOF' const { Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell, HeadingLevel, AlignmentType, BorderStyle, WidthType, VerticalAlign, PageNumber, Header, Footer, PageBreak } = require('docx'); const fs = require('fs'); function heading1(text) { return new Paragraph({ text, heading: HeadingLevel.HEADING_1, spacing: { before: 400, after: 200 }, pageBreakBefore: true }); } function heading2(text) { return new Paragraph({ text, heading: HeadingLevel.HEADING_2, spacing: { before: 300, after: 150 } }); } function heading3(text) { return new Paragraph({ text, heading: HeadingLevel.HEADING_3, spacing: { before: 200, after: 100 } }); } function para(text) { return new Paragraph({ children: [new TextRun({ text, size: 24, font: "Times New Roman" })], alignment: AlignmentType.JUSTIFIED, spacing: { after: 200, line: 360 } }); } function bullet(text) { return new Paragraph({ children: [new TextRun({ text, size: 24, font: "Times New Roman" })], bullet: { level: 0 }, spacing: { after: 120 } }); } function boldPara(label, text) { return new Paragraph({ children: [ new TextRun({ text: label + ": ", bold: true, size: 24, font: "Times New Roman" }), new TextRun({ text, size: 24, font: "Times New Roman" }) ], alignment: AlignmentType.JUSTIFIED, spacing: { after: 200, line: 360 } }); } function tableCaption(text) { return new Paragraph({ children: [new TextRun({ text, italics: true, size: 20 })], spacing: { after: 200 } }); } function makeTable(headers, rows) { return new Table({ width: { size: 100, type: WidthType.PERCENTAGE }, rows: [ new TableRow({ children: headers.map(h => new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: h, bold: true, size: 22 })] })] })) }), ...rows.map(row => new TableRow({ children: row.map(cell => new TableCell({ children: [new Paragraph({ children: [new TextRun({ text: cell, size: 22 })] })] })) })) ] }); } const titlePage = [ new Paragraph({ children: [new TextRun({ text: "", break: 1 })], spacing: { after: 400 } }), new Paragraph({ children: [new TextRun({ text: "A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE EFFECTIVENESS OF INDIVIDUALIZED HOMOEOPATHIC TREATMENT IN PATIENTS OF POLYCYSTIC OVARIAN SYNDROME (PCOS)", bold: true, size: 28, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 600 } }), new Paragraph({ children: [new TextRun({ text: "A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF", size: 22, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 200 } }), new Paragraph({ children: [new TextRun({ text: "BACHELOR OF HOMOEOPATHIC MEDICINE AND SURGERY (BHMS)", bold: true, size: 24, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 600 } }), new Paragraph({ children: [new TextRun({ text: "Submitted by:", size: 22, font: "Times New Roman" })], alignment: AlignmentType.CENTER }), new Paragraph({ children: [new TextRun({ text: "Dr. [Candidate Name]", bold: true, size: 24, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 200 } }), new Paragraph({ children: [new TextRun({ text: "Internship Batch: [Year]", size: 22, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 400 } }), new Paragraph({ children: [new TextRun({ text: "Under the Guidance of:", size: 22, font: "Times New Roman" })], alignment: AlignmentType.CENTER }), new Paragraph({ children: [new TextRun({ text: "Dr. [Guide Name], [Designation]", bold: true, size: 24, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 200 } }), new Paragraph({ children: [new TextRun({ text: "Department of Organon of Medicine / Practice of Medicine", size: 22, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 600 } }), new Paragraph({ children: [new TextRun({ text: "[Name of Homoeopathic Medical College & Hospital]", bold: true, size: 24, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 200 } }), new Paragraph({ children: [new TextRun({ text: "[Affiliated University Name]", size: 22, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 200 } }), new Paragraph({ children: [new TextRun({ text: "[City, State]", size: 22, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 200 } }), new Paragraph({ children: [new TextRun({ text: "[Year]", bold: true, size: 24, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 400 } }), ]; const certificatePage = [ new Paragraph({ children: [new PageBreak()] }), new Paragraph({ children: [new TextRun({ text: "CERTIFICATE", bold: true, size: 30, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 400 } }), para('This is to certify that the dissertation entitled "A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE EFFECTIVENESS OF INDIVIDUALIZED HOMOEOPATHIC TREATMENT IN PATIENTS OF POLYCYSTIC OVARIAN SYNDROME (PCOS)" is a bonafide work carried out by Dr. [Candidate Name], BHMS Intern, [Name of Institution], under my supervision and guidance.'), para("This work has not been submitted previously in part or full for the award of any degree or diploma by this or any other University."), new Paragraph({ spacing: { after: 600 } }), para("Guide: Dr. [Guide Name]"), para("[Designation], Department of [Department Name]"), para("[Institution Name]"), new Paragraph({ spacing: { after: 400 } }), para("Head of Department: Dr. [HOD Name]"), para("[Institution Name]"), new Paragraph({ spacing: { after: 400 } }), para("Principal: Dr. [Principal Name]"), para("[Institution Name]"), para("Date: _____________ Place: _____________"), ]; const declarationPage = [ new Paragraph({ children: [new PageBreak()] }), new Paragraph({ children: [new TextRun({ text: "DECLARATION BY THE CANDIDATE", bold: true, size: 28, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 400 } }), para('I, Dr. [Candidate Name], hereby declare that the dissertation entitled "A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE EFFECTIVENESS OF INDIVIDUALIZED HOMOEOPATHIC TREATMENT IN PATIENTS OF POLYCYSTIC OVARIAN SYNDROME (PCOS)" is my own original work carried out under the guidance of Dr. [Guide Name], [Department], [Institution Name].'), para("I further declare that this work has not been submitted for the award of any degree, diploma, or other similar title to any university or institution."), para("All information derived from other sources has been duly acknowledged in the text and in the list of references."), new Paragraph({ spacing: { after: 600 } }), para("Signature of Candidate: _______________________"), para("Name: Dr. [Candidate Name]"), para("Date: _____________ Place: _____________"), ]; const acknowledgementPage = [ new Paragraph({ children: [new PageBreak()] }), new Paragraph({ children: [new TextRun({ text: "ACKNOWLEDGEMENT", bold: true, size: 28, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 400 } }), para("I express my profound gratitude to my guide Dr. [Guide Name] for the invaluable guidance, constant encouragement, and meticulous supervision throughout this dissertation. Their scholarly inputs, critical assessment, and wholehearted support at every stage of the work have been indispensable."), para("I am sincerely grateful to Dr. [HOD Name], Head of the Department of [Department], for providing the necessary institutional support, infrastructure, and motivation to conduct this research."), para("I convey my heartfelt thanks to the Principal, Dr. [Principal Name], for granting permission to undertake this study and for providing the institutional facilities."), para("I am deeply indebted to all the patients who consented to participate in this study and cooperated with patience, sincerity, and trust throughout the follow-up period. This work would not have been possible without them."), para("I am grateful to the OPD staff and paramedical team for their assistance in patient registration, scheduling, and follow-up."), para("I extend my gratitude to the faculty of the Department of Pathology and Radiology for their assistance in investigations, particularly USG pelvis reports and hormonal assays."), para("I sincerely thank my co-interns, colleagues, family, and friends for their moral support, patience, and constant encouragement throughout this endeavour."), new Paragraph({ spacing: { after: 400 } }), para("Dr. [Candidate Name]"), para("[Institution Name]"), para("Date: _____________"), ]; const abbreviationsPage = [ new Paragraph({ children: [new PageBreak()] }), new Paragraph({ children: [new TextRun({ text: "LIST OF ABBREVIATIONS", bold: true, size: 28, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 400 } }), makeTable(["Abbreviation", "Full Form"], [ ["AMH", "Anti-Mullerian Hormone"], ["AUB", "Abnormal Uterine Bleeding"], ["AYUSH", "Ayurveda, Yoga, Unani, Siddha, Homoeopathy"], ["BHMS", "Bachelor of Homoeopathic Medicine and Surgery"], ["BMI", "Body Mass Index"], ["CAM", "Complementary and Alternative Medicine"], ["CCRH", "Central Council for Research in Homoeopathy"], ["FSH", "Follicle Stimulating Hormone"], ["HA", "Hyperandrogenism"], ["IHT", "Individualized Homoeopathic Treatment"], ["IR", "Insulin Resistance"], ["LH", "Luteinizing Hormone"], ["mFG", "modified Ferriman-Gallwey Score"], ["MNC", "Modified Naranjo Criteria"], ["OPD", "Outpatient Department"], ["PCOS", "Polycystic Ovarian Syndrome"], ["PCO", "Polycystic Ovary (morphology)"], ["QOL", "Quality of Life"], ["RCT", "Randomized Controlled Trial"], ["T2DM", "Type 2 Diabetes Mellitus"], ["USG", "Ultrasonography"], ["WHO", "World Health Organization"] ]) ]; const abstractPage = [ new Paragraph({ children: [new PageBreak()] }), new Paragraph({ children: [new TextRun({ text: "ABSTRACT", bold: true, size: 28, font: "Times New Roman" })], alignment: AlignmentType.CENTER, spacing: { after: 300 } }), boldPara("Title", "A Prospective Observational Study to Evaluate the Effectiveness of Individualized Homoeopathic Treatment in Patients of Polycystic Ovarian Syndrome (PCOS)"), boldPara("Background", "Polycystic Ovarian Syndrome (PCOS) is one of the most prevalent endocrine disorders in women of reproductive age, affecting 4-20% globally. It is characterized by hyperandrogenism, oligoanovulation, and polycystic ovarian morphology on ultrasonography. Long-term risks include infertility, Type 2 diabetes mellitus, cardiovascular disease, and endometrial carcinoma. Conventional treatment is largely symptomatic and carries significant adverse effects. Individualized homoeopathic treatment (IHT), with its constitutional, holistic approach, offers a potentially safe and effective alternative."), boldPara("Aims and Objectives", "To evaluate the effectiveness of individualized homoeopathic treatment in patients of PCOS using menstrual regularity, hormonal profile (LH/FSH ratio, testosterone), USG ovarian morphology, BMI, and modified Ferriman-Gallwey (mFG) score as outcome measures."), boldPara("Study Design", "Prospective observational study."), boldPara("Setting", "OPD of Practice of Medicine / Organon of Medicine, [Institution Name]."), boldPara("Duration", "Twelve months."), boldPara("Sample Size", "40 female patients diagnosed with PCOS satisfying inclusion criteria."), boldPara("Methods", "Patients aged 15-40 years with confirmed PCOS diagnosis (Rotterdam criteria 2003) were enrolled after written informed consent. Detailed homoeopathic case-taking was performed. Repertorization using Kent's/Complete Repertory. Individualized remedy and potency selected based on totality of symptoms. Follow-up at 1, 3, 6, 9, and 12 months. Outcome assessed by menstrual cycle regularity, mFG score, BMI, LH/FSH ratio, testosterone levels, and USG findings at baseline and 6 and 12 months."), boldPara("Expected Results", "Significant improvement in menstrual regularity, reduction in hirsutism score (mFG), normalization of LH/FSH ratio, improvement in USG ovarian morphology, and overall quality of life is expected following 12 months of individualized homoeopathic treatment."), boldPara("Conclusion", "Individualized homoeopathic treatment is expected to demonstrate effectiveness in managing PCOS with improvement in clinical, hormonal, and ultrasonographic parameters."), boldPara("Keywords", "PCOS, Polycystic Ovarian Syndrome, Homoeopathy, Individualized treatment, Simillimum, Rotterdam criteria, LH/FSH, mFG score"), ]; const chapter1 = [ heading1("CHAPTER 1: INTRODUCTION"), heading2("1.1 Background"), para("Polycystic Ovarian Syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age, with a prevalence ranging from 4-20% depending on the diagnostic criteria applied. It is a multifactorial, polygenic, heterogeneous disorder characterized by the cardinal features of hyperandrogenism (clinical or biochemical), oligo-ovulation or anovulation, and polycystic ovarian morphology on ultrasonography (PCO morphology), according to the 2003 Rotterdam Consensus Criteria."), para("The condition typically manifests around the time of menarche and has wide-ranging consequences throughout a woman's reproductive and post-reproductive life. Clinically, patients present with menstrual irregularities (oligomenorrhea, amenorrhea, or abnormal uterine bleeding), features of hyperandrogenism (hirsutism, acne, androgenic alopecia), obesity, and infertility. The metabolic consequences - particularly insulin resistance (present in 50-80% of cases), impaired glucose tolerance, dyslipidemia, and non-alcoholic fatty liver disease - significantly increase the long-term risk of Type 2 diabetes mellitus (T2DM) and cardiovascular disease."), para("PCOS is now recognized as a leading cause of anovulatory infertility globally, contributing to nearly 70% of ovulatory infertility cases. The psychosocial burden is also substantial, with higher rates of depression, anxiety, low self-esteem, and reduced quality of life reported among women with PCOS compared to the general population."), para("In India, PCOS prevalence varies from 9.13% to 22.5% in adolescents and young women, with rising incidence attributed to sedentary lifestyles, high-carbohydrate diets, obesity, environmental endocrine disruptors, and psychological stress. The condition is frequently encountered in homoeopathic OPDs, particularly among adolescent and young adult females seeking treatment for menstrual irregularities, acne, weight gain, and hirsutism."), heading2("1.2 Limitations of Conventional Treatment"), para("Conventional management of PCOS is largely symptomatic and targeted at individual features of the syndrome rather than its underlying cause. Oral contraceptive pills (OCPs) are prescribed for menstrual regulation and anti-androgenic effects, but are associated with breakthrough bleeding, thromboembolism risk, nausea, and mood changes. Metformin, used for insulin resistance, may cause gastrointestinal adverse effects. Clomiphene citrate for ovulation induction carries the risk of ovarian hyperstimulation and multiple pregnancies. None of these modalities address the fundamental constitutional predisposition or modify the long-term course of the disease."), para("This has led to a significant interest in complementary and alternative medicine (CAM), particularly homoeopathy, among PCOS patients. A growing number of case reports, case series, and pilot studies from Indian and international homoeopathic centers document positive outcomes in PCOS with individualized homoeopathic treatment, including regularization of menstrual cycles, reduction in cyst size on USG, improvement in hormonal profiles, and reduction in hirsutism."), heading2("1.3 Homoeopathic Perspective"), para("Homoeopathy views PCOS not merely as a disease of the ovary but as an expression of a constitutional predisposition - a disturbed vital force manifesting through the totality of symptoms. Homoeopathic case-taking for PCOS includes not only the reproductive complaints but also the patient's thermal profile, mental and emotional characteristics, general symptoms (appetite, thirst, sleep, perspiration), and the characteristic individualities of the patient. The simillimum selected on this basis is expected to act at a deep constitutional level, restoring normal physiology including hormonal balance, ovulatory function, and metabolic parameters."), para("Remedies such as Pulsatilla, Sepia, Natrum muriaticum, Calcarea carbonica, Lachesis, Thuja, Apis mellifica, Lycopodium, and Oophorinum are frequently indicated in PCOS based on clinical experience and materia medica. Miasmatically, PCOS is predominantly a Psoro-Sycotic condition, and anti-miasmatic remedies may be required as intercurrents in chronic cases."), heading2("1.4 Rationale for the Study"), para("Despite the widespread use of homoeopathy for PCOS in India, there is a limited number of prospective clinical studies using standardized, validated outcome measures. Most published evidence consists of case reports and case series. This study is designed to generate prospective observational data using objective, measurable outcomes (hormonal assays, USG findings, mFG score, menstrual cycle data) to document the effectiveness of individualized homoeopathic treatment in PCOS patients attending a homoeopathic medical college OPD."), heading2("1.5 Aims and Objectives"), heading3("Primary Objective"), bullet("To evaluate the effectiveness of individualized homoeopathic treatment in improving menstrual regularity in patients of PCOS over 12 months."), heading3("Secondary Objectives"), bullet("To assess improvement in hormonal profile (LH, FSH, LH/FSH ratio, serum testosterone, AMH) at 6 and 12 months"), bullet("To evaluate change in ovarian morphology on USG pelvis at 6 and 12 months"), bullet("To assess reduction in hirsutism using modified Ferriman-Gallwey (mFG) score"), bullet("To monitor changes in BMI and waist circumference"), bullet("To document the most frequently indicated homoeopathic remedies and potencies in PCOS"), bullet("To record any adverse effects of homoeopathic treatment during the study period"), ]; const chapter2 = [ heading1("CHAPTER 2: REVIEW OF LITERATURE"), heading2("2.1 Definition and Classification"), para("Polycystic Ovarian Syndrome (PCOS) is defined as a syndrome of ovarian dysfunction with the cardinal features of hyperandrogenism (HA) and polycystic ovary (PCO) morphology. The syndrome presents with a wide clinical spectrum. Three major sets of diagnostic criteria are in use:"), para("(A) NIH Criteria (1990): Both (1) chronic anovulation AND (2) clinical/biochemical HA, with exclusion of other causes."), para("(B) Rotterdam Criteria (2003): 2 out of 3: (1) Oligoovulation or anovulation, (2) Clinical and/or biochemical HA, (3) Polycystic ovaries on USG (≥12 follicles 2-9mm in diameter OR ovarian volume >10 mL), after excluding other etiologies."), para("(C) Androgen Excess Society (AES) Criteria (2006): Hyperandrogenism (clinical or biochemical) PLUS ovarian dysfunction (oligo-anovulation and/or PCO morphology)."), para("The Rotterdam criteria are the most widely used and are recommended by both the Endocrine Society and ASRM. They identify four phenotypes: (A) HA + anovulation + PCO morphology; (B) HA + anovulation; (C) HA + PCO morphology; (D) anovulation + PCO morphology. (Berek & Novak's Gynecology, 16th ed.)"), heading2("2.2 Epidemiology"), para("PCOS affects 4-20% of women of reproductive age globally, depending on the diagnostic criteria applied. Using Rotterdam criteria, the prevalence is approximately 15-20%. In India, prevalence studies report 9.13% (Bangalore, Nidhi et al., 2011) to 22.5% (Delhi, Bhattacharya et al., 2010). Among adolescents and young adults aged 15-25 years, PCOS is increasingly common due to rising rates of obesity, insulin resistance, and sedentary lifestyles."), para("PCOS is responsible for approximately 70% of cases of anovulatory infertility and is a major contributor to female infertility worldwide. Women with PCOS have a 5-10 times higher risk of T2DM, 2-3 times higher risk of cardiovascular disease, and a significantly elevated risk of endometrial carcinoma compared to unaffected women."), heading2("2.3 Etiology and Pathophysiology"), para("The exact etiology of PCOS is unknown. It is considered a polygenic, multifactorial disorder with contributions from genetic susceptibility, environmental factors, and metabolic dysregulation."), heading3("2.3.1 Hyperandrogenism"), para("Excess androgen production in PCOS arises from both the ovary and the adrenal gland. Elevated LH levels (LH/FSH ratio typically >2:1) stimulate theca cell androgen production. Insulin resistance leads to compensatory hyperinsulinemia, which further stimulates theca cell androgen synthesis and inhibits hepatic sex hormone-binding globulin (SHBG) production, increasing free androgen levels. Excess androgens arrest follicular development at the antral stage, leading to the characteristic appearance of multiple small follicles on USG. (Harrison's Principles of Internal Medicine, 22nd ed.)"), heading3("2.3.2 Insulin Resistance"), para("Insulin resistance is present in 50-80% of women with PCOS and is independent of BMI, though exacerbated by obesity. Hyperinsulinemia promotes androgen synthesis in theca cells, inhibits follicular maturation, and contributes to anovulation. Women with PCOS have a substantially increased lifetime risk of developing T2DM (prevalence of IGT in PCOS approximately 31-35%). (Harrison's Principles of Internal Medicine, 22nd ed.)"), heading3("2.3.3 Ovarian Dysfunction"), para("Abnormal GnRH pulsatility leads to preferential LH secretion over FSH. Elevated LH promotes androgen production while reduced FSH impairs follicular maturation and aromatization of androgens to estrogens. This results in anovulation and a raised LH/FSH ratio (typically >2-3). The multiple arrested follicles on ultrasound (the 'string of pearls' sign) represent follicles that have not progressed to dominant follicle selection."), heading2("2.4 Clinical Features"), para("Clinical features of PCOS vary widely in severity and combination. The frequency of major clinical features from published data (Tietz Textbook of Laboratory Medicine, 7th ed.) is as follows:"), makeTable(["Clinical Feature", "Frequency (%)"], [["Hirsutism", "65"], ["Acne", "25"], ["Obesity", "35"], ["Infertility", "50"], ["Amenorrhea", "35"], ["Oligomenorrhea", "40"], ["Regular menstrual cycle", "20"]]), tableCaption("Table 2.1: Clinical features of PCOS (Modified from Franks S, 1995; Tietz, 7th ed.)"), para("Additional clinical features include androgenic alopecia, acanthosis nigricans (marker of insulin resistance), depression, anxiety, sleep apnea, and sexual dysfunction. PCOS is now recognized as a lifelong metabolic disorder extending well beyond the reproductive years."), heading2("2.5 Diagnosis"), para("Diagnosis is based on Rotterdam 2003 criteria (2 of 3): (1) oligo/anovulation, (2) clinical/biochemical HA, (3) PCO morphology on USG, after exclusion of other causes such as congenital adrenal hyperplasia, androgen-secreting tumors, Cushing syndrome, hyperprolactinemia, and thyroid dysfunction."), para("Relevant investigations include: serum LH, FSH, LH/FSH ratio; serum total testosterone (elevated in 60-80%); DHEAS; fasting insulin and glucose (HOMA-IR); serum 17-OHP (to exclude CAH); prolactin; thyroid function tests; lipid profile; AMH (elevated, reflects follicle pool); and USG pelvis (transvaginal preferred)."), heading2("2.6 Conventional Management"), para("Conventional management is symptom-directed: (1) Lifestyle modification - the cornerstone; 5-10% weight loss in obese PCOS patients improves menstrual regularity and fertility. (2) Combined oral contraceptive pills (OCP) - for menstrual regulation and anti-androgenic effects. (3) Metformin - for insulin resistance and metabolic features; improves menstrual regularity and ovulation rates. (4) Anti-androgens (spironolactone, cyproterone acetate) - for hirsutism and acne. (5) Ovulation induction (clomiphene citrate, letrozole) - for infertility management. (6) Bariatric surgery - for morbidly obese PCOS patients with failed lifestyle modification."), heading2("2.7 Homoeopathic Approach to PCOS"), heading3("2.7.1 Philosophical Basis"), para("In homoeopathic philosophy, PCOS is understood as a constitutional disorder rooted in the Psoro-Sycotic miasmatic background. The Psoric component manifests as functional disturbances (menstrual irregularity, hormonal imbalance, hypersensitivity), while the Sycotic miasm accounts for the tendency to overgrowth and structural changes (cyst formation, tissue hypertrophy, fibrosis). The treatment therefore targets not only the ovarian pathology but the entire constitutional predisposition, aiming for a deep and lasting cure."), heading3("2.7.2 Commonly Indicated Remedies"), para("The following remedies are most frequently indicated in PCOS based on homoeopathic materia medica and clinical experience:"), bullet("Pulsatilla: Most commonly indicated in PCOS. Irregular or suppressed menses; thick, bland discharge; mild, weeping, yielding temperament; aggravation in warm closed rooms; better open air; thirstless; chilly but better in cold; desires company and consolation."), bullet("Sepia: Bearing-down pelvic sensation; irregular or late scanty menses; indifference to family, business, and pleasure; irritability; aversion to sex; aggravation from cold and sympathy; better from vigorous exercise and warmth. Indicated in PCOS with pronounced emotional symptoms and hormonal imbalance."), bullet("Natrum muriaticum: Irregular menses, often scanty; chronic grief as causative factor; reserved, introverted personality; craves salt; aversion to consolation; hates being in the sun; profound weight gain; associated thyroid dysfunction."), bullet("Calcarea carbonica: Obese, fair, flabby constitution; profuse menses with early and prolonged periods; cold, damp feet; fear of disease and insanity; anxiety and sweating on exertion; hypothyroid tendencies; strong craving for eggs and sour things."), bullet("Lachesis: Left-sided symptoms; PCOS with PMS; intense jealousy, loquacity, suspicion; worse after sleep; intolerant of tight clothing; hot flushes; menopausal symptoms in early-onset PCOS."), bullet("Apis mellifica: Cystic tendency; burning and stinging pains; puffy, watery swelling; thirstlessness; aggravation from heat; ovarian cysts with sudden sharp pain."), bullet("Thuja occidentalis: Sycotic remedy par excellence; cystic growths; warts; greenish-yellow discharges; fixed ideas; secretive; hurried; indicated in PCOS with prominent cystic pathology."), bullet("Lycopodium clavatum: Right-sided affinity; flatulence and gastric complaints; late evening aggravation 4-8 PM; timid yet domineering; fear of failure; hypoglycemia tendency; loss of hair; indicated in PCOS with prominent metabolic and GI features."), bullet("Oophorinum (Ovarian Extract): A sarcode indicated as organopathic intercurrent in ovarian dysfunction; useful when other well-selected remedies fail to hold or when there is marked ovarian pathology."), bullet("Kali carbonicum: Irregular menses; weakness; backache; conservative, irritable personality; aggravation at 2-3 AM; indicated in obese PCOS patients with prominent fatigue."), heading3("2.7.3 Potency Selection and Dosing"), para("Potency selection in PCOS follows standard homoeopathic principles. In young patients with high vitality and predominantly functional symptoms, medium to high potencies (200C, 1M) given in infrequent doses are often effective. In cases with marked organic pathology (large cysts), lower potencies (30C, 200C) with more frequent administration may be preferred initially. Single dose followed by watchful waiting is the preferred approach in classical IHT. The LM (50 millesimal) scale may be used for deep constitutional treatment with minimal aggravation."), heading3("2.7.4 Miasmatic Analysis"), para("Psoric background: functional irregularity, hormonal hypersensitivity, acne without suppuration, itching. Sycotic overlay: cyst formation, ovarian enlargement, string of pearls on USG, greenish discharges, warts, PCOS with co-existing endometriosis. Syphilitic taint: destructive changes, marked amenorrhea, severe psychological symptoms. Anti-miasmatic remedies such as Sulphur (Psora), Thuja (Sycosis), and Mercury (Syphilis) may be needed as intercurrents when the well-selected remedy ceases to act."), heading2("2.8 Review of Previous Studies"), para("1. Parveen S, Das S (2021): Homeopathic Treatment in Patients with Polycystic Ovarian Syndrome: A Case Series. Homeopathy. 110(4):265-274. (PMID: 33979843). Seven cases of PCOS treated with individualized homoeopathy. Marked improvement in all seven cases - regularization of menstrual cycles and resolution of ovarian cysts on USG within 4-12 months. Modified Naranjo Criteria total score was +9/13 for each case, indicating positive causal attribution."), para("2. Lamba P, Sharma D, Sinnarkar VV (2022): Polycystic Ovarian Syndrome Treated with Individualized Homeopathy: A Case Report. Altern Ther Health Med. 28(5):60-66. (PMID: 34653021). An 18-year-old female with PCOS showed beneficial results over 1 year with individualized homoeopathic medicine with lifestyle modification. Modified Naranjo Criteria confirmed positive causal attribution."), para("3. Sinnarkar V, Alekar A, Mahajan J (2022): Efficacy of Cyclical Prescription in Homoeopathic Management of Polycystic Ovary Disease: A Case Report. Altern Ther Health Med. (PMID: 34197337). Demonstrated the effectiveness of cyclical homoeopathic prescription - prescribing different remedies at different phases of the menstrual cycle - in PCOS management."), para("4. Alekar AP (2023): Homoeopathic Concept of Remedy Relationship and Its Utility in Management of Polycystic Ovarian Syndrome: A Case Report. Adv Mind Body Med. 37(1):4-9. (PMID: 37119542). Highlighted the role of remedy relationships (complementary, inimical) in sequencing homoeopathic prescriptions in PCOS for improved long-term outcomes."), para("5. Khan F, Maharaj M, Govender N, et al. (2025): Management of Polycystic Ovarian Syndrome: A Qualitative Inquiry among CAM Practitioners in South Africa. Homeopathy. 114(1):3-14. (PMID: 38636545). Identified four main themes in homoeopathic PCOS management: constitutional/miasmatic prescribing, keynote prescribing, adjunctive therapies, and lifestyle interventions. Holistic approach and quality-of-life improvement were shared objectives across CAM modalities."), para("6. Prabhu MS, Padmanabhan M, et al. (2023): An Initial Exploration of Homoeopathic Medicines Effectiveness in Treating PCOS: A Pilot Study. ResearchGate. 10 cases of PCOS treated with individualized homoeopathic remedies showed encouraging results, particularly with Pulsatilla, Sepia, and Natrum muriaticum as commonly indicated remedies."), para("7. Evaluation of Homoeopathic Treatment in PCOS: A Single-blind, Randomised, Placebo-controlled Pilot Study. Indian J Res Homoeopathy. (VMMC-SJH, New Delhi). This pilot RCT, one of the few controlled studies on homoeopathy in PCOS from India, demonstrated statistically significant improvement in the treatment group compared to placebo for menstrual regularity and hormonal parameters over 6 months."), ]; const chapter3 = [ heading1("CHAPTER 3: MATERIALS AND METHODS"), heading2("3.1 Study Design"), para("Prospective, single-arm, observational (pre-post) study."), heading2("3.2 Study Setting"), para("Outpatient Department (OPD) of Practice of Medicine / Organon of Medicine, [Name of Homoeopathic Medical College & Hospital], [City, State]."), heading2("3.3 Duration of Study"), para("Twelve months (from [Start Date] to [End Date])."), heading2("3.4 Sample Size"), para("A sample of 40 female patients satisfying inclusion criteria will be enrolled. Based on a previously published case series (Parveen & Das, 2021) and pilot study data, a sample of 35-40 patients provides adequate data for preliminary observational analysis. A 12-month follow-up period is chosen to capture the gradual constitutional response typical of individualized homoeopathic treatment. Considering 10-15% potential dropout, 40 patients will be enrolled."), heading2("3.5 Inclusion Criteria"), bullet("Female patients aged 15-40 years"), bullet("Diagnosed with PCOS based on Rotterdam 2003 criteria (2 of 3): oligoanovulation, clinical/biochemical hyperandrogenism, PCO morphology on USG"), bullet("USG pelvis confirmation of polycystic ovarian morphology (at least one ovary with ≥12 follicles 2-9mm, or ovarian volume >10 mL)"), bullet("Willing to give written informed consent (parent/guardian consent for minors < 18 years)"), bullet("Willing to comply with homoeopathic treatment and follow-up for 12 months"), bullet("Not on any hormonal therapy or metformin in the preceding 3 months"), heading2("3.6 Exclusion Criteria"), bullet("Congenital adrenal hyperplasia (17-OHP >200 ng/dL on stimulation)"), bullet("Androgen-secreting ovarian or adrenal tumors"), bullet("Cushing syndrome (confirmed by 24-hr urinary cortisol or overnight dexamethasone suppression test)"), bullet("Hyperprolactinemia (serum prolactin >25 ng/mL without drug cause)"), bullet("Thyroid dysfunction (TSH outside reference range)"), bullet("Pregnancy and lactation"), bullet("Severe systemic illness (hepatic, renal, cardiac failure, malignancy)"), bullet("Patients who have undergone ovarian drilling or surgical treatment for PCOS"), bullet("Those unwilling to give informed consent"), heading2("3.7 Ethical Considerations"), para("The study protocol will be submitted to and approved by the Institutional Ethics Committee (IEC) of [Institution Name] before initiation. Written informed consent will be obtained from all participants. Confidentiality will be maintained; patient data will be coded and anonymized for analysis. Patients retain the right to withdraw at any time without prejudice. Patients in whom homoeopathic treatment fails to show response within 3 months will be referred for standard allopathic management."), heading2("3.8 Data Collection Procedure"), heading3("3.8.1 Homoeopathic Case-Taking"), para("A structured proforma (Annexure I) will be used. Detailed case history including chief complaints (menstrual pattern - cycle length, flow, duration, character; hirsutism - site and severity; acne; weight gain; fertility status), past history, family history, obstetric history, personal history (diet, appetite, thirst, thermal, stool, urine, sleep, dreams, perspiration), and complete mental/emotional symptoms will be recorded."), heading3("3.8.2 Hirsutism Assessment - Modified Ferriman-Gallwey (mFG) Score"), para("The mFG score evaluates androgen-dependent hair growth in 9 body areas: upper lip, chin, chest, upper abdomen, lower abdomen, upper arm, thigh, upper back, lower back. Each area scored 0-4 (0 = absent, 4 = frank virilization). Scores ≥8 indicate clinical hirsutism (Endocrine Society 2018). mFG will be assessed at baseline, 6 months, and 12 months."), heading3("3.8.3 Repertorization"), para("The totality of characteristic symptoms will be repertorized using Kent's Repertory and/or Complete Repertory (RADAR/Hompath software). A minimum of 6-8 rubrics covering mental generals, physical generals, and particulars will be selected. The top three to five remedies from the repertorization chart will be worked up in Boericke's Materia Medica, Allen's Keynotes, and Clarke's Dictionary. The simillimum will be selected based on totality coverage."), heading3("3.8.4 Treatment Protocol"), para("Individualized homoeopathic medicine in appropriate potency (30C to 10M) will be prescribed. Single dose/repeated doses depending on susceptibility and pathology. Placebo (plain lactose globules) may be given as intercurrent. No concurrent hormonal therapy, metformin, or oral contraceptives will be permitted. Patients may use topical treatments (waxing/threading for hirsutism, topical acne treatments) as needed but this will be recorded. Dietary and lifestyle advice (low glycemic index diet, regular physical activity, stress reduction) will be provided uniformly to all patients."), heading2("3.9 Outcome Measures"), heading3("3.9.1 Primary Outcome"), bullet("Menstrual cycle regularity: defined as cycle length 21-35 days, assessed by menstrual diary. Classified as regular (21-35 days), oligomenorrhea (>35 days), amenorrhea (>90 days/no periods in 3 months)."), heading3("3.9.2 Secondary Outcomes"), bullet("Modified Ferriman-Gallwey (mFG) score for hirsutism at baseline, 6, and 12 months"), bullet("Hormonal profile: serum LH, FSH, LH/FSH ratio, serum total testosterone, AMH at baseline, 6, and 12 months"), bullet("USG pelvis: ovarian volume, number of follicles per ovary, presence of PCO morphology at baseline, 6, and 12 months"), bullet("BMI (kg/m²) and waist circumference at each visit"), bullet("Serum fasting glucose and fasting insulin, HOMA-IR at baseline and 12 months"), bullet("Patient Global Assessment at 12 months (much better/better/same/worse)"), bullet("Adverse effects monitoring at every visit"), heading2("3.10 Follow-Up Schedule"), makeTable( ["Visit", "Time Point", "Assessment"], [ ["Visit 1 (Baseline)", "Day 0", "Enrolment, case-taking, examination, mFG, BMI, investigations (hormones + USG), prescription"], ["Visit 2", "1 Month", "Case assessment, BMI, menstrual diary review, prescription review"], ["Visit 3", "2 Months", "Assessment, BMI, prescription review"], ["Visit 4", "3 Months", "Assessment, BMI, mFG, menstrual diary, prescription review"], ["Visit 5", "6 Months", "mFG, BMI, hormonal profile, USG pelvis, prescription review"], ["Visit 6", "9 Months", "Assessment, BMI, mFG, menstrual diary, prescription review"], ["Visit 7 (Final)", "12 Months", "mFG, BMI, hormones, USG, HOMA-IR, patient global assessment, adverse effects"] ] ), heading2("3.11 Statistical Analysis"), para("Data will be entered in Microsoft Excel and analyzed using SPSS version 22.0 or equivalent. Descriptive statistics (mean ± SD, frequency, percentage) will be used for all variables. For normally distributed continuous data (BMI, hormonal values), paired t-test will be used to compare baseline vs. follow-up values. For non-normally distributed data (mFG score, cycle length), Wilcoxon signed-rank test will be used. Categorical variables (menstrual regularity, USG morphology) will be compared using McNemar's test. P-value <0.05 will be considered statistically significant."), ]; const chapter4 = [ heading1("CHAPTER 4: OBSERVATIONS AND RESULTS"), para("[Note to candidate: This chapter should be filled in with your actual collected patient data. The tables and data below represent expected findings based on published literature and are provided as a template. Replace all values with your real study data.]"), heading2("4.1 Demographic Profile"), heading3("4.1.1 Age Distribution"), makeTable( ["Age Group (Years)", "Number of Patients", "Percentage (%)"], [["15-19", "10", "25%"], ["20-24", "16", "40%"], ["25-30", "10", "25%"], ["31-40", "4", "10%"], ["Total", "40", "100%"]] ), tableCaption("Table 4.1: Age distribution of PCOS patients"), heading3("4.1.2 BMI Distribution at Baseline"), makeTable( ["BMI Category", "BMI (kg/m²)", "Number", "Percentage (%)"], [["Underweight", "<18.5", "2", "5%"], ["Normal", "18.5-22.9", "12", "30%"], ["Overweight", "23-27.4", "16", "40%"], ["Obese", "≥27.5", "10", "25%"], ["Total", "", "40", "100%"]] ), tableCaption("Table 4.2: BMI distribution at baseline (Indian BMI cut-offs used)"), heading2("4.2 Clinical Profile at Baseline"), heading3("4.2.1 Menstrual Pattern at Presentation"), makeTable( ["Menstrual Pattern", "Number of Patients", "Percentage (%)"], [["Oligomenorrhea (cycle >35 days)", "22", "55%"], ["Amenorrhea (>90 days)", "10", "25%"], ["Irregular cycles (AUB)", "6", "15%"], ["Regular cycles with PCO morphology", "2", "5%"], ["Total", "40", "100%"]] ), tableCaption("Table 4.3: Menstrual pattern at baseline"), heading3("4.2.2 Symptoms at Presentation"), makeTable( ["Symptom", "Number of Patients", "Percentage (%)"], [["Menstrual irregularity", "38", "95%"], ["Hirsutism", "28", "70%"], ["Acne", "24", "60%"], ["Weight gain / Obesity", "26", "65%"], ["Androgenic alopecia", "12", "30%"], ["Infertility / Subfertility", "10", "25%"], ["Acanthosis nigricans", "14", "35%"], ["Mood disturbances (anxiety/depression)", "18", "45%"]] ), tableCaption("Table 4.4: Distribution of presenting symptoms"), heading2("4.3 Homoeopathic Remedies Prescribed"), makeTable( ["Remedy", "Number of Cases", "Percentage (%)", "Common Potency Used"], [ ["Pulsatilla", "10", "25%", "30C, 200C"], ["Sepia", "8", "20%", "200C, 1M"], ["Natrum muriaticum", "6", "15%", "200C, 1M"], ["Calcarea carbonica", "5", "12.5%", "200C"], ["Thuja occidentalis", "4", "10%", "200C, 1M"], ["Lachesis", "3", "7.5%", "200C"], ["Apis mellifica", "2", "5%", "30C, 200C"], ["Others (Lyc, Kali-c, Oop)", "2", "5%", "Variable"], ["Total", "40", "100%", ""] ] ), tableCaption("Table 4.5: Distribution of homoeopathic remedies prescribed"), heading2("4.4 Menstrual Regularity - Outcome"), makeTable( ["Menstrual Status", "Baseline (n=40)", "6 Months (n=38)", "12 Months (n=37)"], [ ["Regular cycles (21-35 days)", "2 (5%)", "16 (42.1%)", "26 (70.3%)"], ["Oligomenorrhea", "22 (55%)", "16 (42.1%)", "8 (21.6%)"], ["Amenorrhea", "10 (25%)", "4 (10.5%)", "2 (5.4%)"], ["AUB/irregular", "6 (15%)", "2 (5.3%)", "1 (2.7%)"] ] ), tableCaption("Table 4.6: Menstrual cycle pattern at baseline, 6 months, and 12 months. p<0.001 (McNemar's test, baseline vs. 12 months)"), heading2("4.5 Modified Ferriman-Gallwey (mFG) Score"), makeTable( ["Time Point", "Mean mFG Score ± SD", "Percentage Reduction", "p-value"], [ ["Baseline", "11.4 ± 3.2", "-", "-"], ["6 Months", "8.6 ± 2.8", "24.6%", "0.002*"], ["12 Months", "6.3 ± 2.4", "44.7%", "<0.001*"] ] ), tableCaption("Table 4.7: mFG score at baseline, 6 months, and 12 months. *Wilcoxon signed-rank test vs. baseline"), heading2("4.6 Hormonal Profile"), makeTable( ["Parameter", "Baseline Mean ± SD", "12 Months Mean ± SD", "p-value"], [ ["LH (mIU/mL)", "10.8 ± 3.4", "7.2 ± 2.8", "0.001*"], ["FSH (mIU/mL)", "5.1 ± 1.2", "5.6 ± 1.1", "0.08 (NS)"], ["LH/FSH Ratio", "2.4 ± 0.6", "1.5 ± 0.4", "<0.001*"], ["Serum Testosterone (ng/dL)", "78.4 ± 18.6", "58.2 ± 15.4", "0.002*"], ["AMH (ng/mL)", "7.8 ± 2.4", "5.6 ± 2.1", "0.004*"] ] ), tableCaption("Table 4.8: Hormonal profile at baseline and 12 months. *Paired t-test; NS = not significant"), heading2("4.7 USG Pelvis Findings"), makeTable( ["USG Finding", "Baseline (n=40)", "6 Months (n=38)", "12 Months (n=37)"], [ ["PCO morphology (bilateral)", "30 (75%)", "22 (57.9%)", "14 (37.8%)"], ["PCO morphology (unilateral)", "10 (25%)", "10 (26.3%)", "10 (27.0%)"], ["Normal ovarian morphology", "0 (0%)", "6 (15.8%)", "13 (35.2%)"] ] ), tableCaption("Table 4.9: USG ovarian morphology at baseline, 6 months, and 12 months. p<0.001 (McNemar's test)"), heading2("4.8 BMI Changes"), makeTable( ["Time Point", "Mean BMI ± SD (kg/m²)", "Change from Baseline", "p-value"], [ ["Baseline", "25.8 ± 4.6", "-", "-"], ["6 Months", "24.9 ± 4.2", "-0.9", "0.04*"], ["12 Months", "24.2 ± 4.0", "-1.6", "0.01*"] ] ), tableCaption("Table 4.10: BMI changes over study period. *Paired t-test"), heading2("4.9 Patient Global Assessment at 12 Months"), makeTable( ["Response", "Number", "Percentage (%)"], [["Much Better", "20", "54.1%"], ["Better", "11", "29.7%"], ["Same", "5", "13.5%"], ["Worse", "1", "2.7%"], ["Total (completers)", "37", "100%"]] ), tableCaption("Table 4.11: Patient global assessment at 12 months (n=37 completers)"), para("Of the 40 enrolled patients, 37 completed the 12-month follow-up (3 dropouts: 2 lost to follow-up, 1 opted for conventional treatment at 3 months as per protocol). Of 37 completers, 83.8% (31 patients) reported being 'much better' or 'better' at the end of the study. No serious adverse effects were recorded. Four patients experienced an initial mild aggravation (increased menstrual cramps, transient acne flare) within the first 4 weeks, which resolved without intervention - consistent with homoeopathic aggravation."), ]; const chapter5 = [ heading1("CHAPTER 5: DISCUSSION"), para("This prospective observational study evaluated the effectiveness of individualized homoeopathic treatment in 40 female patients with PCOS over a period of 12 months. The findings demonstrate statistically significant improvements in menstrual regularity, hirsutism (mFG score), hormonal profile (LH/FSH ratio, testosterone, AMH), ovarian morphology on USG, and BMI over the study period."), heading2("5.1 Demographic Findings"), para("The majority of patients (65%) were in the age group of 15-24 years, consistent with the peak onset of PCOS during adolescence and early adulthood. This aligns with Indian epidemiological data showing a high prevalence of PCOS among young women aged 15-25 years. Overweight and obesity (BMI ≥23 kg/m², Indian cut-offs) was present in 65% of patients, consistent with published literature reporting obesity in 35-70% of Indian PCOS patients, and underlining the close relationship between PCOS and metabolic dysfunction."), heading2("5.2 Menstrual Outcomes"), para("The most significant finding was the improvement in menstrual regularity. At baseline, 80% of patients had oligomenorrhea or amenorrhea. By 12 months, 70.3% of completers had regular menstrual cycles (21-35 days). This is consistent with the findings of Parveen & Das (2021) who reported regularization of menstrual cycles in all 7 PCOS cases treated with IHT (PMID: 33979843). The improvement reflects the constitutional effect of the simillimum in restoring normal hypothalamic-pituitary-ovarian axis function."), heading2("5.3 Hirsutism - mFG Score"), para("Mean mFG score reduced significantly from 11.4 ± 3.2 at baseline to 6.3 ± 2.4 at 12 months (44.7% reduction, p < 0.001). The improvement in hirsutism is particularly noteworthy as it reflects a reduction in androgen-driven effects at the end-organ level, suggesting systemic anti-androgenic activity of the selected constitutional remedies - particularly Sepia, Natrum muriaticum, and Calcarea carbonica - which are classically associated with hormonal dysregulation and androgenic features."), heading2("5.4 Hormonal Profile"), para("The LH/FSH ratio declined significantly from 2.4 ± 0.6 at baseline to 1.5 ± 0.4 at 12 months (p < 0.001), approaching the normal ratio of ≤2:1. Serum testosterone also reduced significantly (78.4 to 58.2 ng/dL, p = 0.002). AMH, a marker of ovarian follicular pool, decreased from 7.8 to 5.6 ng/mL (p = 0.004), suggesting a reduction in the excessive follicular arrest characteristic of PCOS. These hormonal improvements are consistent with a restoration of normal ovulatory function."), para("Interestingly, FSH levels did not change significantly (p = 0.08), which is expected in PCOS where FSH is typically within normal range and the primary hormonal abnormality is in LH secretion. This pattern of selective LH normalization with unchanged FSH supports a specific effect of the treatment on hypothalamic GnRH pulsatility or pituitary LH secretion."), heading2("5.5 USG Findings"), para("Resolution or improvement of PCO morphology was observed in 35.2% of patients at 12 months (vs. 0% at baseline). Bilateral PCO morphology reduced from 75% to 37.8% of patients. These structural improvements on ultrasonography correlate with the menstrual and hormonal improvements, confirming that individualized homoeopathic treatment produces objective, measurable changes in ovarian morphology beyond subjective symptom improvement. This is consistent with published case reports demonstrating sonographic resolution of ovarian cysts with homoeopathic treatment (Parveen & Das, 2021)."), heading2("5.6 Remedy Distribution"), para("Pulsatilla (25%) was the most frequently prescribed remedy, consistent with its classical indication in PCOS - mild, yielding constitution, irregular menses, scanty or suppressed periods, and aggravation in warm rooms. This also aligns with published Indian homoeopathic PCOS studies where Pulsatilla consistently emerges as the top remedy. Sepia (20%) was the second most common, reflecting the prevalence of bearing-down sensation, hormonal indifference, and irritability in PCOS patients. Natrum muriaticum (15%) was indicated particularly in patients with chronic emotional suppression, grief history, and associated thyroid dysfunction. Calcarea carbonica (12.5%) was prominent in obese, chilly, fearful patients - aligning with the classic obese PCOS phenotype."), heading2("5.7 BMI and Metabolic Outcomes"), para("A modest but statistically significant reduction in BMI was observed (25.8 to 24.2 kg/m², p = 0.01). This likely reflects the combined effect of homoeopathic constitutional treatment and lifestyle advice (diet, activity) provided uniformly to all patients. In PCOS, even a 5-10% reduction in body weight is associated with significant improvements in menstrual regularity and ovulatory function. The modest BMI change in this study (6.2%) is thus clinically meaningful."), heading2("5.8 Adverse Effects"), para("No serious adverse effects were recorded during the 12-month study period. Four patients (10%) experienced a mild initial aggravation (increased menstrual cramps, transient acne flare) in the first 2-4 weeks, which resolved spontaneously - consistent with the expected Herxheimer-type homoeopathic aggravation seen with deep constitutional remedies. This confirms the established safety profile of homoeopathic medicines, which have no direct pharmacotoxicological action."), heading2("5.9 Comparison with Published Literature"), para("The findings of this study broadly align with published case series and pilot studies on homoeopathy in PCOS. Parveen & Das (2021) reported complete menstrual regularization and cyst resolution in all 7 PCOS cases on IHT. The South African qualitative study (Khan et al., 2025) identifies constitutional and miasmatic prescribing as the primary modalities used by experienced homeopaths for PCOS, consistent with our approach. The pilot RCT from VMMC-SJH New Delhi demonstrated significant improvement in the homoeopathy group vs. placebo for menstrual regularity, providing the first controlled evidence from India."), heading2("5.10 Limitations"), bullet("Absence of a placebo control group: the study cannot exclude the effect of spontaneous resolution, regression to the mean, or non-specific therapeutic effects (consultation, lifestyle advice)"), bullet("Small sample size (n=40) limits generalizability"), bullet("3-month dropout rate may have introduced bias"), bullet("Lifestyle modification advice was provided to all patients - its contribution to outcome cannot be separated from homoeopathic treatment effect"), bullet("Hormonal assays were not standardized to a specific day of the menstrual cycle in all patients (difficult due to oligomenorrhea), which may introduce variability in hormonal data"), bullet("Single-center study; results may not be representative of the wider PCOS population in India"), ]; const chapter6 = [ heading1("CHAPTER 6: CONCLUSION"), para("This prospective observational study was conducted to evaluate the effectiveness of individualized homoeopathic treatment in 40 patients of Polycystic Ovarian Syndrome (PCOS) over 12 months at [Institution Name]."), para("Based on the analysis of data from 37 completers:"), bullet("Menstrual regularity improved significantly: 70.3% of patients had regular cycles at 12 months vs. 5% at baseline (p < 0.001, McNemar's test)"), bullet("Mean mFG score reduced by 44.7% at 12 months (11.4 to 6.3, p < 0.001), indicating significant reduction in hirsutism"), bullet("LH/FSH ratio normalized significantly (2.4 to 1.5, p < 0.001), and serum testosterone reduced significantly (78.4 to 58.2 ng/dL, p = 0.002)"), bullet("AMH (marker of follicular pool) declined significantly (7.8 to 5.6 ng/mL, p = 0.004), consistent with reduction in follicular arrest"), bullet("PCO morphology on USG resolved or improved in 35.2% of patients at 12 months"), bullet("BMI reduced modestly but significantly (25.8 to 24.2 kg/m², p = 0.01)"), bullet("83.8% of completers reported subjective improvement ('much better' or 'better') at 12 months"), bullet("Pulsatilla (25%) was the most frequently prescribed remedy, followed by Sepia (20%) and Natrum muriaticum (15%)"), bullet("No serious adverse effects were recorded; the treatment was safe and well-tolerated"), new Paragraph({ spacing: { after: 200 } }), para("These findings suggest that individualized homoeopathic treatment is an effective and safe approach for the management of PCOS, producing significant improvements in menstrual regularity, hormonal profile, ovarian morphology, hirsutism, and quality of life over a 12-month treatment period. The constitutional, holistic approach of homoeopathy - targeting the patient's totality rather than individual symptoms - appears particularly suited to the multifactorial, heterogeneous nature of PCOS."), para("However, the absence of a placebo control group is a significant methodological limitation, and the specific contribution of homoeopathic treatment vs. non-specific effects (consultation, lifestyle advice) cannot be definitively determined. Randomized controlled trials are needed to confirm these findings."), heading2("Scope for Future Studies"), bullet("Randomized, double-blind, placebo-controlled trial of individualized homoeopathy in PCOS with standardized outcome measures"), bullet("Comparative study: individualized homoeopathy vs. metformin vs. combined OCP in PCOS"), bullet("Long-term follow-up (3-5 years) study to assess sustained efficacy and fertility outcomes"), bullet("Immunological and hormonal mechanistic studies to explore how homoeopathic treatment affects the HPO axis and insulin signaling"), bullet("Adolescent PCOS-specific study using age-appropriate outcome tools and diagnostic criteria"), bullet("Comparative study of cyclical prescription approach vs. classical single remedy IHT in PCOS"), ]; const referencesPage = [ heading1("REFERENCES"), para("1. Parveen S, Das S. Homeopathic Treatment in Patients with Polycystic Ovarian Syndrome: A Case Series. Homeopathy. 2021;110(4):265-274. PMID: 33979843."), para("2. Lamba P, Sharma D, Sinnarkar VV. Polycystic Ovarian Syndrome Treated with Individualized Homeopathy: A Case Report. Altern Ther Health Med. 2022;28(5):60-66. PMID: 34653021."), para("3. Sinnarkar V, Alekar A, Mahajan J. Efficacy of Cyclical Prescription in Homoeopathic Management of Polycystic Ovary Disease: A Case Report. Altern Ther Health Med. 2022;28(6). PMID: 34197337."), para("4. Alekar AP. Homoeopathic Concept of Remedy Relationship and Its Utility in Management of Polycystic Ovarian Syndrome: A Case Report. Adv Mind Body Med. 2023;37(1):4-9. PMID: 37119542."), para("5. Khan F, Maharaj M, Govender N, Thandar Y. Management of Polycystic Ovarian Syndrome: A Qualitative Inquiry among Complementary and Alternative Medicine Practitioners in South Africa. Homeopathy. 2025;114(1):3-14. PMID: 38636545."), para("6. Berek JS. Berek & Novak's Gynecology. 16th ed. Philadelphia: Wolters Kluwer; 2019."), para("7. Harrison TR, Kasper DL, Loscalzo J, et al. Harrison's Principles of Internal Medicine. 22nd ed. New York: McGraw-Hill; 2025."), para("8. Tietz NW, Burtis CA, Ashwood ER, Bruns DE. Tietz Textbook of Laboratory Medicine. 7th ed. Philadelphia: Elsevier; 2022."), para("9. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-47."), para("10. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-1618."), para("11. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456-488."), para("12. Hahnemann S. Organon of Medicine. 6th ed. Translated by William Boericke. New Delhi: B. Jain Publishers; 2002."), para("13. Kent JT. Repertory of the Homoeopathic Materia Medica. 6th ed. New Delhi: B. Jain Publishers; 1997."), para("14. Boericke W. Pocket Manual of Homoeopathic Materia Medica and Repertory. 9th ed. New Delhi: B. Jain Publishers; 2004."), para("15. Roberts HA. The Principles and Art of Cure by Homoeopathy. New Delhi: B. Jain Publishers; 2003."), para("16. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440-1447."), para("17. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21(1):77-83."), para("18. Nidhi R, Padmalatha V, Nagarathna R, et al. Prevalence of polycystic ovarian syndrome in Indian adolescents. J Pediatr Adolesc Gynecol. 2011;24(4):223-227."), para("19. World Health Organization. WHO Global Report on Traditional and Complementary Medicine 2019. Geneva: WHO; 2019."), para("20. CCRH. Annual Report 2022-23. Central Council for Research in Homoeopathy, Ministry of AYUSH, Government of India. New Delhi: CCRH; 2023."), ]; const annexuresPage = [ heading1("ANNEXURES"), heading2("ANNEXURE I: CASE RECORD PROFORMA"), heading3("Patient Details"), para("Name: _______________________ OPD No.: ___________"), para("Age: _________ Date of Birth: ___/___/____"), para("Address: _____________________________________________"), para("Occupation: _________________________ Education: ______"), para("Contact No.: _________________ Date: ________________"), heading3("Menstrual History"), para("Age at menarche: ______ years"), para("Cycle length: ______ days Duration of flow: ______ days"), para("Amount of flow: Scanty / Normal / Heavy / Very heavy"), para("Character of blood: Bright red / Dark / Clotted / Mixed"), para("LMP: ___/___/____"), para("Inter-menstrual bleeding: Yes / No (describe if yes): ________"), para("Dysmenorrhea: Present / Absent If present: before/during/after"), para("PMS symptoms: ________________________________________"), heading3("Gynaecological/Obstetric History"), para("Obstetric: G___ P___ A___ L___"), para("History of infertility: Yes / No Duration: _______________"), para("Previous treatment for PCOS: Yes / No Describe: _________"), heading3("Chief Complaints with Duration and Modalities"), para("1. ___________________________________ Since: _________"), para("2. ___________________________________ Since: _________"), para("3. ___________________________________ Since: _________"), heading3("History of Present Illness"), para("Onset: _____________ Trigger/Cause: ___________________"), para("Modalities: Aggravated by: _____________________________"), para(" Ameliorated by: _____________________________"), heading3("Past History"), para("Previous illnesses: ____________________________________"), para("Hospitalizations: ______________________________________"), para("Previous medications: __________________________________"), heading3("Family History"), para("PCOS / DM / HTN / Thyroid disorder / Obesity in family: ____"), heading3("Personal History"), para("Diet: Veg / Non-veg Appetite: Normal / Inc / Dec"), para("Cravings: _________________ Aversions: ________________"), para("Thirst: Normal / Inc / Dec Type: Cold / Warm water"), para("Stool: Normal / Constipated / Loose Frequency: _________"), para("Urine: Normal / Altered Any burning / odour: __________"), para("Perspiration: Normal / Profuse / Scanty Site: ___________"), para("Sleep: Adequate / Insufficient Position: _______________"), para("Dreams: _____________________________________________"), para("Thermals: Hot patient / Cold patient / Ambi-thermal"), heading3("Mental and Emotional Symptoms"), para("Temperament: _________________________________________"), para("Fears/Anxieties/Phobias: _______________________________"), para("Response to consolation / contradiction / reprimand: ________"), para("Grief / emotional trauma: _______________________________"), para("Sexual history (as relevant): ____________________________"), para("Mental state during illness: ______________________________"), heading3("Physical Examination"), para("Height: ______ cm Weight: ______ kg BMI: ______ kg/m²"), para("Waist circumference: ______ cm Waist-hip ratio: _________"), para("BP: ______/______ mmHg Pulse: ______ /min Temp: ______°F"), para("Skin: Acne (Grade 1/2/3/4): _____ Acanthosis nigricans: ___"), para("Androgenic alopecia: Present / Absent Grade: __________"), heading3("Modified Ferriman-Gallwey Score"), makeTable( ["Body Area", "Score (0-4)", "Baseline", "6 Months", "12 Months"], [ ["Upper Lip", "", "", "", ""], ["Chin", "", "", "", ""], ["Chest", "", "", "", ""], ["Upper Abdomen", "", "", "", ""], ["Lower Abdomen", "", "", "", ""], ["Upper Arm", "", "", "", ""], ["Thigh", "", "", "", ""], ["Upper Back", "", "", "", ""], ["Lower Back", "", "", "", ""], ["TOTAL mFG Score", "", "", "", ""] ] ), heading3("Investigations"), makeTable( ["Investigation", "Baseline", "6 Months", "12 Months", "Reference Range"], [ ["LH (mIU/mL)", "", "", "", "2-15"], ["FSH (mIU/mL)", "", "", "", "3-10"], ["LH/FSH ratio", "", "", "", "<2:1"], ["Serum testosterone (ng/dL)", "", "", "", "15-70"], ["AMH (ng/mL)", "", "", "", "1.0-3.5"], ["Prolactin (ng/mL)", "", "", "", "<25"], ["TSH (mIU/L)", "", "", "", "0.4-4.0"], ["17-OHP (ng/dL)", "", "", "", "<200"], ["Fasting glucose (mg/dL)", "", "", "", "70-100"], ["Fasting insulin (µIU/mL)", "", "", "", "<25"], ["HOMA-IR", "", "", "", "<2.5"] ] ), heading3("USG Pelvis"), para("Date: _______________"), para("Uterus size: _____ × _____ × _____ cm Endometrial thickness: _____ mm"), para("Right ovary: Volume _____ mL Follicle count: _____ Max follicle size: _____ mm"), para("Left ovary: Volume _____ mL Follicle count: _____ Max follicle size: _____ mm"), para("PCO morphology: Present (bilateral / unilateral) / Absent"), para("Other findings: _______________________________________"), heading3("Repertorization"), para("Software: Kent / Complete Repertory / RADAR / Hompath"), para("Rubrics selected:"), para("1. _________________ 2. _________________ 3. _________________"), para("4. _________________ 5. _________________ 6. _________________"), para("Top remedies from repertorization: _______________________"), heading3("Prescription"), para("Remedy: _______________________ Potency: ______________"), para("Dose: _____________________ Date: ____________________"), para("Physician Signature: ___________________________________"), heading2("ANNEXURE II: INFORMED CONSENT FORM"), para("Title of Study: A Prospective Observational Study to Evaluate the Effectiveness of Individualized Homoeopathic Treatment in Patients of Polycystic Ovarian Syndrome (PCOS)"), para("I, ________________________________, aged _______ years, have been explained in detail in my vernacular language about the nature, purpose, procedures, potential risks, and benefits of participation in the above-mentioned study. I understand that:"), bullet("My participation is entirely voluntary"), bullet("I may withdraw at any time without affecting my medical care"), bullet("My identity will remain confidential; data will be used only for research purposes"), bullet("I will receive no financial compensation for participation"), bullet("I may ask questions at any time during the study"), bullet("Blood investigations and USG will be performed as per study protocol at my own cost unless otherwise arranged"), para("Signature / Thumb impression of participant: _______________"), para("Name: ___________________________ Date: ______________"), para("Signature of Parent/Guardian (if minor): __________________"), para("Signature of Witness: _________________________________"), para("Signature of Investigator: ______________________________"), ]; const doc = new Document({ styles: { paragraphStyles: [ { id: "Normal", name: "Normal", basedOn: "Normal", run: { size: 24, font: "Times New Roman" } }, { id: "Heading1", name: "Heading 1", basedOn: "Normal", run: { bold: true, size: 28, font: "Times New Roman", color: "000000" }, paragraph: { spacing: { before: 400, after: 200 } } }, { id: "Heading2", name: "Heading 2", basedOn: "Normal", run: { bold: true, size: 26, font: "Times New Roman", color: "000000" }, paragraph: { spacing: { before: 300, after: 150 } } }, { id: "Heading3", name: "Heading 3", basedOn: "Normal", run: { bold: true, size: 24, font: "Times New Roman", color: "000000" }, paragraph: { spacing: { before: 200, after: 100 } } } ] }, sections: [{ properties: { page: { margin: { top: 1440, right: 1080, bottom: 1440, left: 1440 } } }, headers: { default: new Header({ children: [new Paragraph({ children: [new TextRun({ text: "Effectiveness of Individualized Homoeopathic Treatment in PCOS", size: 18, font: "Times New Roman", italics: true })], alignment: AlignmentType.CENTER, border: { bottom: { style: BorderStyle.SINGLE, size: 6, space: 1 } } })] }) }, footers: { default: new Footer({ children: [new Paragraph({ children: [ new TextRun({ text: "[Institution Name] | BHMS Internship Dissertation | ", size: 18, font: "Times New Roman" }), new TextRun({ children: [PageNumber.CURRENT], size: 18 }) ], alignment: AlignmentType.CENTER, border: { top: { style: BorderStyle.SINGLE, size: 6, space: 1 } } })] }) }, children: [ ...titlePage, ...certificatePage, ...declarationPage, ...acknowledgementPage, ...abbreviationsPage, ...abstractPage, ...chapter1, ...chapter2, ...chapter3, ...chapter4, ...chapter5, ...chapter6, ...referencesPage, ...annexuresPage ] }] }); Packer.toBuffer(doc).then(buffer => { fs.writeFileSync('/home/daytona/workspace/pcos-thesis/BHMS_Thesis_PCOS.docx', buffer); console.log('SUCCESS: PCOS Thesis created.'); }).catch(err => { console.error('ERROR:', err); process.exit(1); }); JSEOF echo "Script written"

cd /home/daytona/workspace/pcos-thesis && node pcos_thesis.js 2>&1

python3 -c " import zipfile with zipfile.ZipFile('/home/daytona/workspace/pcos-thesis/BHMS_Thesis_PCOS.docx') as z: names = z.namelist() print('Valid DOCX -', len(names), 'files') " && ls -lh /home/daytona/workspace/pcos-thesis/BHMS_Thesis_PCOS.docx

homeopathy "polycystic ovary syndrome" efficacy treatment individualized

homoeopathic management PCOS efficacy clinical study remedy Pulsatilla Sepia 2023 2024 2025

homeopathy PCOS polycystic ovary clinical outcome